See veebileht kasutab küpsiseid kasutaja sessiooni andmete hoidmiseks. Veebilehe kasutamisega nõustute ETISe kasutustingimustega. Loe rohkem
Olen nõus

Irja Lutsar

https://etis.ee/CV/Irja_Lutsar/est
20.07.1954
737 4171
irja.lutsar@ut.ee

Teenistuskäik

Töökohad ja ametid
11.01.2016–...   
Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut, osakonna juhataja
01.01.2016–...   
Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut, meditsiinilise mikrobioloogia professor (1,00)
01.01.2016–10.01.2016   
Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut, osakonna juhataja
01.09.2014–31.12.2015   
Tartu Ülikool, Arstiteaduskond, Mikrobioloogia instituut, meditsiinilise mikrobioloogia professor (1,00)
01.09.2014–31.12.2015   
Tartu Ülikool, Arstiteaduskond, Mikrobioloogia instituut, instituudi juhataja
01.09.2012–31.08.2014   
Tartu Ülikool, Arstiteaduskond, Mikrobioloogia instituut, instituudi juhataja
01.09.2009–31.08.2014   
Tartu Ülikool, Arstiteaduskond, Mikrobioloogia instituut, meditsiinilise mikrobioloogia ja viroloogia professor (1,00)
01.09.2009–31.08.2012   
Tartu Ülikool, Arstiteaduskond, Mikrobioloogia instituut, instituudi juhataja
01.11.2007–31.08.2009   
Tartu Ülikool, Arstiteaduskond, Mikrobioloogia instituut, instituudi juhataja
01.11.2004–31.10.2007   
Tartu Ülikool, Arstiteaduskond, Mikrobioloogia instituut, instituudi juhataja
25.10.2004–31.08.2009   
Tartu Ülikool, Arstiteaduskond, Mikrobioloogia instituut, meditsiinilise mikrobioloogia ja viroloogia professor (1,00)
01.01.2003–31.12.2004   
pediaatrilise programmi juht. Pfizer Ltd, Sandwich, Inglismaa
01.01.1999–31.12.2003   
kliinilise projekti juht, Pfizer Ltd., Global Research and Development, UK
01.01.1998–31.12.1999   
assistent, nakkusbloki juhataja, Tartu Ülikooli Lastekliinik
01.01.1995–31.12.1998   
Fellow in paediatric infectious diseases, Southwestern Medical Center at Dallas, USA
01.01.1992–31.12.1995   
nakkusosakonna juhataja, laste nakkushaiguste konsultant, Tartu Ülikooli Lastekliinik
01.01.1982–31.12.1992   
peaarsti asetäitja ravi alal, nakkuskorpuse juhataja, Tartu Linna Kliiniline Lastehaigla
01.01.1979–31.12.1982   
pediaater,Võru Rajooni Keskhaigla
01.01.1978–31.12.1979   
Tallinna 1. Lastehaigla, intern
 
 
Haridustee
1995–1998   
Post-dok laste nakkushaigustes - Southwestern Medical School, Dallas, Texas, USA
1992–1995   
Tartu Ülikooli Arstitaduskond, doktoriõpe - PhD
1978–1979   
Pediaatriline internatuur
1972–1978   
Tartu Ülikooli Arstiteaduskonna pediaatriaosakond, MD
 
 
Teadusorganisatsiooniline ja -administratiivne tegevus
2015−...   
The Paediatric Infectious Disease Journal, sektsiooni toimetaja
2012−...   
Eesti Teadusagentuur, Hindamisnõukogu liige
2011−...   
Tartu Ülikooli senati liige
2007−...   
Euroopa Ravimiamet (EMEA), Pediaatriline komitee liige
2010−2013   
Euroopa laste Infektsioonhaiguste Selts (ESPID) - juhatuse liige
2006−2012   
Eesti Teadusfond, Terviseuuringute Ekspertkomitee, esimees
2005−2010   
Euroopa Ravimiamet (EMEA), antimikroobsete ainete ekspertgrupp, liige
2002−2005   
ESPID (European Society for Pediatric Infectious Diseases) teaduskomisjoni liige
1998−1999   
Eesti Infektsionistide Seltsi juhatuse president 1998-1999
1994−1994   
Eesti Lastearstide Kongress, Tallinn - korralduskomitee liige
1993−1993   
Balti Lasteneuroloogide Assotsiatsiooni Teine Konverents, Riia - korralduskomitee liige
1993−1993   
Rahvusvaheline sümpoosium “Impact of the environment to children’s health” Tartu , peasekretär
1992−1994   
Eesti Infektsionistide Seltsi juhatuse liige
1991−1991   
Balti Lasteneuroloogide Assotsiatsiooni Esimene Konverents, Tartu - peasekretär
1990−1995   
Eesti Lastearstide Seltsi juhatuse liige
1990−1993   
Balti Lasteneuroloogide Seltsi juhatuse liige aastatel
1989−1989   
Eesti Lastearstide Kongress, Tallinn - korralduskomitee liige

Kvalifikatsioon

Teaduskraadid
Irja Lutsar, doktorikraad, 1995, (juh) Tiina Talvik, Kesknärvisüsteemi põletikulised haigused lastel (kliinilis-epidemioloogiline iseloomustus ja kaugtulemused), Tartu Ülikool, Arstiteaduskond.
 
 
Teaduspreemiad ja tunnustused
2014, Irja Lutsar, Tartu Ülikooli suur medal
2013, Irja Lutsar, Eesti Vabariigi Punase Risti II klassi orden
2010, Irja Lutsar, Eesti Riigi Teaduspreemia
2010, Irja Lutsar, Uurimuste tsükli «Infektsioonide käsitlus omandatud immuunpuudulikkusega isikutel» eest
1995, Irja Lutsar, European Society for Pediatric Infectious Diseases uurimispreemia
1994, Irja Lutsar, Eesti Vabariigi Teaduspreemia (uurimisgrupi liige), 1994European Society for Pediatric Infectious Diseases preemia uurimistööks, 1995
 
 
Teadustöö põhisuunad
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; CERCS KLASSIFIKAATOR: B510 Nakkushaigused
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.11. Terviseuuringutega seotud uuringud, näiteks biokeemia, geneetika, mikrobioloogia, biotehnoloogia, molekulaarbioloogia, rakubioloogia, biofüüsika ja bioinformaatika; TÄPSUSTUS: HIV infektsiooni molekulaarepidemioloogia ja ravimresistentsuse kujunemine.
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; TÄPSUSTUS: Neonataalse perioodi infektsioonid, patogeenees ning ravi. Kesknärvisüsteemi infektsioonid lastel - patogenees, ravi ja kaugtulemused. Antibiootikumide farmakokineetilised ja farmakodünaamilised omadused lastel. Antibakteriaalsete ravimite kliiniline efektiivsus.
 
 
Lisainfo
Ei ole lisainfot

Jooksvad projektid

Lõppenud projektid

Juhendamisel väitekirjad

Juhendatud väitekirjad

Publikatsioonid

Klass
Aasta
Publikatsioon
 
2.4.
2022
Merits, Andres; Abroi, Aare; Kurg, Reet; Žusinaite, Eva; Truve, Erkki; Sarmiento, Cecilia; Sõmera, Merike; Saar, Tiiu; Viltrop, Arvo; Lutsar, Irja; Avi, Radko; Karki, Tõnis; Huik, Kristi; Kõljalg, Siiri; Brilene, Tatjana; Roots, Irja;Inno, Heleri (2022). Üldine ja Meditsiiniline viroloogia. Tartu: Tartu Ülikooli kirjastus [ilmumas].
1.1.
2020
Jõgi, Piia; Soeorg, Hiie; Oona, Marje; Kaart, Tanel; Toompere, Karolin; Maskina, Tereza; Koort, Iris; Rätsep, Anneli; Lutsar, Irja; , (2020). Dynamics of pertussis toxin IgG after symptomatic pertussis in children and adults. Vaccine, 38 (16), 3196−3200. DOI: 10.1016/j.vaccine.2020.02.080.
1.1.
2020
Lutsar, Irja; Chazallon, Corine; Trafojer, Ursula; de Cabre, Vincent Meiffredy; Auriti, Cinzia; Bertaina, Chiara; Calo Carducci, Francesca Ippolita; Canpolat, Fuat Emre; Esposito, Susanna; Fournier, Isabelle; Hallik, Maarja; Heath, Paul T; Ilmoja, Mari-Liis; Iosifidis, Elias; Kuznetsova, Jelena; Meyer, Laurence; Metsvaht, Tuuli; Mitsiakos, George; Pana, Zoi Dorothea; Mosca, Fabio ... , (2020). Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial. PLoS ONE, 15 (3), e0229380−e0229380. DOI: 10.1371/journal.pone.0229380.
1.1.
2020
Kõivumägi, Kadri; Toompere, Karolin; Soeorg, Hiie; Kallas, Eveli; Jõgeda, Ene-Ly; Huik, Kristi; Lutsar, Irja (2020). Acute gastroenteritis hospitalizations after implementation of universal mass vaccination against rotavirus. Vaccine, 38 (13), 2879−2886. DOI: 10.1016/j.vaccine.2020.01.098.
1.1.
2020
Andersen, Petter I.; Ianevski, Aleksandr; Lysvand, Hilde; Vitkauskiene, Astra; Oksenych, Valentyn; Bjørås, Magnar; Telling, Kaidi; Lutsar, Irja; Dampis, Uga; Irie, Yasuhiko; Tenson, Tanel; Kantele, Anu; Kainov, Denis E. (2020).

Discovery and development of safe-in-man broad-spectrum antiviral agents

. International Journal of Infectious Diseases, 93, 268−276. DOI: 10.1016/j.ijid.2020.02.018.
1.1.
2020
Telling, Kaidi; Brauer, Age; Laht, Mailis; Kalmus, Piret; Toompere, Karolin; Kisand, Veljo; Maimets, Matti; Remm, Maido; Tenson, Tanel; Lutsar, Irja (2020). Characteristics of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae and Contact to Animals in Estonia. Microorganisms, 8 (8). DOI: 10.3390/microorganisms8081130.
5.2.
2020
Tiit-Vesingi, Annika; Soeorg, Hiie; Truusalu, Kai; Hoidmets, Dagmar; Rööp, Tiiu; Laas, Hanna-Kadri; Lutsar, Irja; Metsvaht, Tuuli (2020). Staphylococcus epidermidis’e suur genotüübiline mitmekesisus perekeskses vastsündinute intensiivravi osakonnas. Eesti Arst, 99 (Lisa 2): Tartu Ülikooli arstiteaduskonna aastapäeva teaduskonverents 2020; Tartu, Eesti; 15.-16. oktoober 2020. OÜ Celsius Healthcare, 24.
1.1.
2019
Soeorg, Hiie; Metsvaht, Hanna Kadri; Keränen, Evamaria Elisabet; Eelmäe, Imbi; Merila, Mirjam; Ilmoja, Mari-Liis; Metsvaht, Tuuli; Lutsar, Irja. (2019). Genetic Relatedness of Staphylococcus haemolyticus in Gut and Skin of Preterm Neonates and Breast Milk of Their Mothers. The Pediatric Infectious Disease Journal.10.1097/INF.0000000000002056.
1.1.
2019
Huik, Kristi; Soodla, Pilleriin; Pauskar, Merit; Owen, S. Michele; Luo, Wei; Murphy, Gary; Jogeda, Ene-Ly; Kallas, Eveli; Rajasaar, Heli; Avi, Radko; Masciotra, Silvina; Lutsar, Irja; Del Amo, Julia; Meyer, Laurence; Bucher, Heiner C.; Chene, Genevieve; Hamouda, Osamah; Pillay, Deenan; Prins, Maria; Rosinska, Magda ... Scott, Martin (2019). The concordance of the limiting antigen and the Bio-Rad avidity assays in persons from Estonia infected mainly with HIV-1 CRF06_cpx. PLoS ONE, 14 (5), ARTN e0217048. DOI: 10.1371/journal.pone.0217048.
1.1.
2019
Mesek, Inge; Nellis, Georgi; Lass, Jana; Metsvaht, Tuuli; Varendi, Heili; Visk, Helle; Turner, Mark A; Nunn, Anthony J; Duncan, Jennifer; Lutsar, Irja (2019). Medicines prescription patterns in European neonatal units. International Journal of Clinical Pharmacy. DOI: 10.1007/s11096-019-00923-2.
1.1.
2019
Esposito, Susanna; Stefanelli, Paola; Fry, Norman K; Fedele, Giorgio; He, Qiushui; Paterson, Pauline; Tan, Tina; Knuf, Markus; Rodrigo, Carlos; Weil Olivier, Catherine; Flanagan, Katie L; Hung, Ivan; Lutsar, Iria; Edwards, Kathryn; O'Ryan, Miguel; Principi, Nicola; , (2019). Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines. Frontiers in Immunology, 10, 1344−1344.10.3389/fimmu.2019.01344.
1.1.
2019
Jacqz-Aigrain, Evelyne; Leroux, Stéphanie; Thomson, Alison H; Allegaert, Karel; Capparelli, Edmund V; Biran, Valérie; Simon, Nicolas; Meibohm, Bernd; Lo, Yoke-Lin; Marques, Remedios; Peris, José-Esteban; Lutsar, Irja; Saito, Jumpei; Nakamura, Hidefumi; van den Anker, Johannes N; Sharland, Mike; Zhao, Wei (2019). Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. Journal of Antimicrobial Chemotherapy, 74 (8), 2128−2138. DOI: 10.1093/jac/dkz158.
1.1.
2019
Ianevski, Aleksandr; Zusinaite, Eva; Shtaida, Nastassia; Kallio-Kokko, Hannimari; Valkonen, Miia; Kantele, Anu; Telling, Kaidi; Lutsar, Irja; Letjuka, Pille; Metelitsa, Natalja; Oksenych, Valentyn; Dumpis, Uga; Vitkauskiene, Astra; Stašaitis, Kestutis; Öhrmalm, Christina; Bondeson, Kåre; Bergqvist, Anders; Cox, Rebecca J; Tenson, Tanel; Merits, Andres ... Kainov, Denis E (2019). Low Temperature and Low UV Indexes Correlated with Peaks of Influenza Virus Activity in Northern Europe during 2010⁻2018. Viruses, 11 (3), 11(3). DOI: 10.3390/v11030207.
1.1.
2019
Folgori, Laura; Lutsar, Irja; Standing, Joseph F; Walker, A Sarah; Roilides, Emmanuel; Zaoutis, Theoklis E; Jafri, Hasan; Giaquinto, Carlo; Turner, Mark A; Sharland, Mike (2019). Standardising neonatal and paediatric antibiotic clinical trial design and conduct: the PENTA-ID network view. BMJ Open, 9 (12), e032592−e032592. DOI: 10.1136/bmjopen-2019-032592.
5.2.
2019
Tiit, Annika; Soeorg, Hiie; Tammaru, Marika; Eelmäe, Imbi; Ilmoja, Mari-Liis; Metsvaht, Tuuli; Lutsar, Irja (2019). Rinnapiima kolonisatsioon mecA-positiivsete koagulaasnegatiivsete stafülokokkidega kolmes vastsündinute intensiivravi osakonnas. Eesti Arst. Eesti Lastearstide Seltsi XXII kongressi teesid, 98 (Lisa 2): Eesti Lastearstide Seltsi XXII Kongress; Tartu, Eesti; 30.05.-01.06.2019. Publicon, 60.
5.2.
2019
Jõgi, P.; Soeorg, H.; Oona, M.; Kaart, T.; Maskina, T.; Koort, I.; Rätsep. A.; Lutsar. I. (2019). Läkaköha toksiini vastaste antikehade püsimine lastel ja täiskasvanutel pärast läkaköha põdemist. Eesti Arst (23−23). Eesti Latearstide Seltsi XXII kongress.
1.1.
2018
P Soodla, R Simmons, K Huik, M Pauskar, E-L Jõgeda, H Rajasaar, E Kallaste, M Maimets, R Avi, G Murphy, K Porter, I Lutsar and for the Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE) Collaboration in EuroCoord (2018). HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay. HIV Medicine, 19 (1), 33−41.10.1111/hiv.12535.
1.1.
2018
Pansa, Paola; Hsia, Yingfen; Bielicki, Julia; Lutsar, Irja; Walker, A Sarah; Sharland, Mike; Folgori, Laura (2018). Evaluating Safety Reporting in Paediatric Antibiotic Trials, 2000-2016: A Systematic Review and Meta-Analysis. Drugs. DOI: 10.1007/s40265-017-0850-x.
1.1.
2018
Padari, Helgi; Metsvaht, Tuuli; Germovsek, Eva; Barker, Charlotte; Kipper, Karin; Herodes, Koit; Standing, Joseph; Oselin, Kersti; Tasa, Tõnis; Soeorg, Hiie; Lutsar, Irja (2018). Pharmacokinetics of penicillin G in preterm and term neonates. Antimicrobial Agents and Chemotherapy.10.1128/AAC.02238-17.
1.1.
2018
Kogermann, Karin; Lass, Jana; Nellis, Georgi; Metsvaht, Tuuli; Lutsar, Irja (2018). Age-appropriate formulations including pharmaceutical excipients in neonatal medicines. Current Pharmaceutical Design, 23, 5779−5789. DOI: 10.2174/1381612823666170926122613.
1.1.
2018
Germovsek, Eva; Lutsar, Irja; Kipper, Karin; Karlsson, Mats O.; Planche, Tim; Chazallon, Corine; Meyer, Laurence; Trafojer, Ursula M. T.; Metsvaht, Tuuli; Fournier, Isabelle; Sharland, Mike; Heath, Paul; Standing, Joseph F.; on behalf of the NeoMero Consortium (2018). Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies. Journal of Antimicrobial Chemotherapy, 73 (Article), 1908−1916.10.1093/jac/dky128.
1.1.
2018
Jõgi, Piia; Oona, Marje; Kaart, Tanel; Toompere, Karolin; Maskina, Tereza; Koort, Iris; Rätsep, Anneli; Lutsar, Irja (2018). Pertussis and parapertussis in children and adults with a persistent cough: an observational study. Infection, 46 (1), 83−91. DOI: 10.1007/s15010-017-1095-z.
1.1.
2018
Ianevski, Aleksandr; Zusinaite, Eva; Kuivanen, Suvi; Strand, Marten; Lysvand, Hilde; Teppor, Mona; Kakkola, Laura; Paavilainen, Henrik; Laajala, Mira; Kallio-Kokko, Hannimari; Valkonen, Miia; Kantele, Anu; Telling, Kaidi; Lutsar, Irja; Letjuka, Pille; Metelitsa, Natalja; Oksenych, Valentyn; Bjoras, Magnar; Nordbo, Svein Arne; Dumpis, Uga ... Kainov, Denis (2018). Novel activities of safe-in-human broad-spectrum antiviral agents. Antiviral Research, 154, 174−182. DOI: 10.1016/j.antiviral.2018.04.016.
1.1.
2018
Soeorg, Hiie; Treumuth, Sirli; Metsvaht, Hanna Kadri; Eelmäe, Imbi; Merila, Mirjam; Ilmoja, Mari-Liis; Lutsar, Irja; Metsvaht, Tuuli. (2018). Higher intake of coagulase-negative staphylococci from maternal milk promotes gut colonization with mecA-negative Staphylococcus epidermidis in preterm neonates. Journal of Perinatology.10.1038/s41372-018-0183-y.
1.1.
2018
Jõgeda, E-L; Avi, R; Pauskar, M; Kallas, E; Karki, T; Des Jarlais, D; Uusküla, A; Toompere, K; Lutsar, I; Huik, K (2018). Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs. Journal of Medical Virology, 90 (11), 1779−1783. DOI: 10.1002/jmv.25258.
1.1.
2018
Dyar, OJ; Nathwani, D; Monnet, DL; Gyssens, IC; Stålsby Lundborg, C; Pulcini, C; ESGAP Student-PREPARE Working Group (2018). Do medical students feel prepared to prescribe antibiotics responsibly? Results from a cross-sectional survey in 29 European countries. Journal of Antimicrobial Chemotherapy, 73 (8), 2236.10.1093/jac/dky150.
1.1.
2018
Parm, Ülle; Štšepetova, Jelena; Eelmäe, Imbi; Merila, Mirjam; Ilmoja, Mari-Liis; Metsvaht, Tuuli; Lutsar, Irja; Soeorg, Hiie (2018). Genetic relatedness of Gram-negative bacteria colonizing gut and skin of neonates and mother's own milk. Journal of Perinatology, 38, 1503−1511. DOI: 10.1038/s41372-018-0220-x.
1.1.
2018
Telling, Kaidi; Laht, Mailis; Brauer, Age; Remm, Maido; Kisand, Veljo; Maimets, Matti; Tenson, Tanel; Lutsar, Irja (2018). Multidrug resistant Pseudomonas aeruginosa in Estonian hospitals. BMC Infectious Diseases, 18 (1), ARTN 513. DOI: 10.1186/s12879-018-3421-1.
5.2.
2018
Lemsalu L, Rice B, Uusküla A, Raag M, Lutsar I, Rüütel K (2018). How to ascertain an accurate number of people living with diagnosed HIV and fill data gaps from the past - lessons learned from a high prevalence setting in Europe. 22nd International AIDS Conference, Amsterdam, the Netherlands, 23-27 July 2018. International AIDS Society.
1.1.
2017
Veigure, Ruta; Aro, Rudolf; Metsvaht, Tuuli; Standing, Joseph F.; Lutsar, Irja; Herodes, Koit; Kipper, Karin (2017). A Highly Sensitive Method for the Simultaneous UHPLC-MS/MS Analysis of Clonidine, Morphine, Midazolam and their Metabolites in Blood Plasma Using HFIP as the Eluent Additive. Journal of Chromatography B, 1052, 150−157. DOI: 10.1016/j.jchromb.2017.03.007.
1.1.
2017
Soeorg H, Huik K, Parm Ü, Ilmoja ML, Metsvaht T, Lutsar I (2017). Molecular epidemiology of Staphylococcus epidermidis in neonatal intensive care units. APMIS, 125, 63−73. DOI: 10.1111/apm.12637.
1.1.
2017
Soeorg, Hiie; Metsvaht, Tuuli; Eelmäe, Imbi; Metsvaht, Hanna Kadri; Treumuth, Sirli; Merila, Mirjam; Ilmoja, Mari-Liis; Lutsar, Irja (2017). Coagulase-Negative Staphylococci in Human Milk From Mothers of Preterm Compared With Term Neonates. Journal of Human Lactation, 33 (2), 329−340. DOI: 10.1177/0890334417691505.
1.1.
2017
Tasa, Tõnis; Metsvaht, Tuuli; Kalamees, Riste; Vilo, Jaak; Lutsar, Irja (2017). DosOpt: A Tool for Personalized Bayesian Dose Adjustment of Vancomycin in Neonates. Therapeutic Drug Monitoring, 39 (6), 604−613. DOI: 10.1097/FTD.0000000000000456.
1.1.
2017
Jogeda, Ene-Ly; Huik, Kristi; Pauskar, Merit; Kallas, Eveli; Karki, Tonis; Jarlais, Don Des; Uuskula, Anneli; Lutsar, Irja; Avi, Radko (2017). Prevalence and Genotypes of GBV-C and Its Associations With HIV Infection Among Persons Who Inject Drugs in Eastern Europe. Journal of Medical Virology, 89 (4), 632−638.10.1002/jmv.24683.
1.1.
2017
Soeorg, Hiie; Metsvaht, Tuuli; Eelmäe, Imbi; Merila, Mirjam; Treumuth, Sirli; Huik, Kristi; Jürna-Ellam, Marika; Ilmoja, Mari-Liis; Lutsar, Irja (2017). The role of breast milk in the colonization of neonatal gut and skin with coagulase-negative staphylococci. Pediatric Research, 82 (5), 759−767.10.1038/pr.2017.150.
1.1.
2017
Thompson, Georgina; Barker, Charlotte I; Folgori, Laura; Bielicki, Julia A; Bradley, John S; Lutsar, Irja; Sharland, Mike (2017). Global shortage of neonatal and paediatric antibiotic trials: rapid review. BMJ Open, 7 (10), e016293−e016293.10.1136/bmjopen-2017-016293.
1.1.
2017
Taba, P; Schmutzhard, E; Forsberg, P; Lutsar, I; Ljøstad, U; Mygland, Å; Levchenko, I; Strle, F; Steiner, I (2017). EAN consensus review on prevention, diagnosis and management of tick-borne encephalitis. European Journal of Neurology, 24 (10), 1214−1e61.10.1111/ene.13356.
5.2.
2017
Jõgi, P.; Oona, M.; Kaart, T.; Toompere, K.; Maskina, T.; Koort, I.; Rätsep, A.; Lutsar, I. (2017). Läkaköha toksiini vastaste IgG-tüüpi antikehade tase läkaköhaga patsientide hulgas ning kolme aasta jooksul pärast haiguse põdemist. 96. Eesti Arst, 16. (Lisa 1).
5.2.
2017
Parm, Ü.; Soeorg, H.; Štšepetova, J.; Metsvaht, T.; Ilmoja, ML.; Lutsar, I. (2017). Gram-negative opportunistic microorganisms colonising the skin and gut of neonates and breast milk of their mothers. European Congress on Clinical Microbiology and Infectious Diseases; 22-25.04.2017. Vienna, Austria.. ECCMID.
5.2.
2017
Metsvaht, Hanna Kadri; Metsvaht, Tuuli; Eelmäe, Imbi; Merila, Mirjam; Lutsar, Irja; Ilmoja, Mari-Liis; Soeorg, Hiie (2017). Skin and gut colonisation with Staphylococcus haemolyticus in term and preterm neonates. European Society for Paediatric Infectious Diseases,.
1.1.
2016
Huik, Kristi; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Jõgeda, Ene-Ly; Karki, Tõnis; Rüütel, Kristi; Talu, Ave; Abel-Ollo, Katri; Uusküla, Anneli; Carrillo, Andrew; Ahuja, Sunil K; He, Weijing; Lutsar, Irja (2016). A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs. PLoS ONE, 11 (6), e0156850−e0156850. DOI: 10.1371/journal.pone.0156850.
1.1.
2016
Germovsek, Eva; Kent, Alison; Metsvaht, Tuuli; Lutsar, Irja; Klein, Nigel; Turner, Mark A; Sharland, Mike; Nielsen, Elisabet I; Heath, Paul T; Standing, Joseph F (2016). Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants. Antimicrobial Agents and Chemotherapy, 60 (8), 4869−4877. DOI: 10.1128/AAC.00577-16.
1.1.
2016
Folgori, Laura; Bielicki, Julia; Ruiz, Beatriz; Turner, Mark A; Bradley, John S; Benjamin, Daniel K; Zaoutis, Theoklis E; Lutsar, Irja; Giaquinto, Carlo; Rossi, Paolo; Sharland, Mike (2016). Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review. The Lancet: Infectious Diseases, 16 (9), 178−189.10.1016/S1473-3099(16)00069-4.
1.1.
2016
Nellis, Georgi; Metsvaht, Tuuli; Varendi, Heili; Lass, Jana; Duncan, Jennifer; Nunn, Anthony J; Turner, Mark A; Lutsar, Irja (2016). Product Substitution as a Way Forward in Avoiding Potentially Harmful Excipients in Neonates. Pediatric Drugs, 18 (3), 221−230. DOI: 10.1007/s40272-016-0173-5.
1.1.
2016
Pantazis, Nikos; Touloumi, Giota; Meyer, Laurence; Olson, Ashley; Costagliola, Dominique; Kelleher, Anthony D; Lutsar, Irja; Chaix, Marie-Laure; Fisher, Martin; Moreno, Santiago; Porter, Kholoud; , (2016). The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. AIDS (London, England), 30 (6), 879−888. DOI: 10.1097/QAD.0000000000000991.
1.1.
2016
Brauer, Age; Telling, Kaidi; Laht, Mailis; Kalmus, Piret; Lutsar, Irja; Remm, Maido; Kisand, Veljo; Tenson, Tanel (2016). Plasmid with colistin resistance gene mcr-1 in ESBL-producing Escherichia coli strains isolated from pig slurry in Estonia. Antimicrobial Agents and Chemotherapy, 60 (11), 6933−36. DOI: 10.1128/AAC.00443-16.
1.1.
2016
Avi, Radko; Pauskar, Merit; Karki, Tõnis; Kallas, Eveli; Jõgeda, Ene-Ly; Margus, Tõnu; Huik, Kristi; Lutsar, Irja (2016). Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia. Journal of Medical Virology, 88 (3), 448−454. DOI: 10.1002/jmv.24361.
1.1.
2016
Kallas, Eveli; Huik, Kristi; Türk, Silver; Pauskar, Merit; Jõgeda, Ene-Ly; Šunina, Marina; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja (2016). T Cell Distribution in Relation to HIV/HBV/HCV Coinfections and Intravenous Drug Use. Viral Immunology, 0−0. DOI: 10.1089/vim.2016.0057.
1.1.
2016
Kallas, Eveli; Huik, Kristi; Türk, Silver; Pauskar, Merit; Jõgeda, Ene-Ly; Šunina, Marina; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja (2016). Differences in T cell distribution and CCR5 expression in HIV-positive and HIV-exposed seronegative persons who inject drugs. Medical microbiology and immunology, 205 (3), 231−239. DOI: 10.1007/s00430-015-0444-8.
1.1.
2016
Jõgeda, Ene-Ly; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Lutsar, Irja; Huik, Kristi (2016). Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe. Infection Genetics and Evolution, 43, 83−85.10.1016/j.meegid.2016.05.022.
1.1.
2016
Padari, Helgi; Oselin, Kersti; Tasa, Tõnis; Metsvaht, Tuuli; Lõivukene, Krista; Lutsar, Irja (2016). Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target? BMC Pediatrics, 16 (1), 206−206. DOI: 10.1186/s12887-016-0753-0.
1.1.
2016
Laisaar, K.T.; Raag, M.; Lutsar, I.; Uusküla, A. (2016). People living with HIV in Estonia: engagement in HIV care in 2013. Eurosurveillance, 21 (43), x−x. DOI: 10.2807/1560-7917.ES.2016.21.43.30380.
5.2.
2016
Soeorg, H.; Metsvaht, T.; Eelmäe, I.; Treumuth, S.; Merila, M.; Ilmoja, ML.; Lutsar, I. (2016). High prevalence of mecA-positive coagulase-negative staphylococci (MR-CoNS) in breast milk (BM) of mothers of preterm neonates. The 34th Annual Meeting of the ESPID, May 10-14, 2016, Brighton, UK. European Society for Paediatric Infectious Diseases,.
5.2.
2016
Mesek, Inge; Nellis, Georgi; Metsvaht, Tuuli; Visk, Helle; Lass, Jana; Lutsar, Irja (2016). The impact of gestational age and geographical region on anti-infectives’ use in European neonatal intensive care units (NICU). In: . 34th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), 10.-14.05.2016, Brighton, UK.
1.1.
2015
Jõgi, P.; Oona, M.; Toompere, K.; Lutsar, I. (2015). Estimated and reported incidence of pertussis in Estonian adults: A seroepidemiological study. Vaccine, 33 (38), 4756−4761. DOI: 10.1016/j.vaccine.2015.08.007.
1.1.
2015
Soodla, P.; Rajasaar, H.; Avi, R.; Zilmer, K.; Kink, K.; Novikova, L.; Huik, K.; Maimets, M.; Lutsar, I. (2015). Design and structure of the Estonian HIV Cohort Study (E-HIV). Infectious Diseases, 47 (11), 768−675. DOI: 10.3109/23744235.2015.1061203.
1.1.
2015
Parm, Ülle; Metsvaht, Tuuli; Ilmoja, Mari-Liis; Lutsar, Irja (2015). Gut colonization by aerobic microorganisms is associated with route and type of nutrition in premature neonates. Nutrition Research, 35 (6), 496−503.10.1016/j.nutres.2015.04.006.
1.1.
2015
Metsvaht, Tuuli; Nellis, Georgi; Varendi, Heili; Nunn, Anthony; Graham, Susan; Rieutord, Andre; Storme, Thomas; McElnay, James; Mulla, Hussain; Turner, Mark; Lutsar, Irja (2015). High variability in the dosing of commonly used antibiotics revealed by a Europewide point prevalence study: implications for research and dissemination. BMC Pediatrics, 15 (41), 1−10. DOI: 10.1186/s12887-015-0359-y.
1.1.
2015
Kallas, E.; Huik, K.; Pauskar, M.; Jõgeda, E.-L.; Karki, T.; Des Jarlais, D.; Uusküla, A.; Avi, R.; Lutsar, I. (2015). Influence of interleukin 10 polymorphisms -592 and -1082 to the HIV, HBV and HCV serostatus among intravenous drug users. Infection Genetics and Evolution, 30, 175−180.10.1016/j.meegid.2014.12.023.
1.1.
2015
Mulla, Hussain; Yakkundi, Shirish; McElnay, James; Lutsar, Irja; Metsvaht, Tuuli; Varendi, Heili; Nellis, Georgi; Nunn, Anthony; Duncan, Jennifer; Pandya, Hitesh; Turner, Mark (2015). An observational study of blood concentrations and kinetics of methyl- and propyl-parabens in neonates. Pharmaceutical Research, 32 (3), 1084−1093. DOI: 10.1007/s11095-014-1520-2.
1.1.
2015
Koljalg, Siiri; Telling, Kaidi; Huik, Kristi; Murruste, Marko; Saarevet, Virve; Pauskar, Merit; Lutsar, Irja (2015). First report of Wohlfahrtiimonas chitiniclastica from soft tissue and bone infection at an unusually high northern latitude. Folia Microbiologica, 60 (2), 155−158.10.1007/s12223-014-0355-x.
1.1.
2015
Rhee, S.-Y.; Blanco, J.L.; Jordan, M.R.; Taylor, J.; Lemey, P.; Varghese, V.; Hamers, R.L.; Bertagnolio, S.; de Wit, T.F.R.; Aghokeng, A.F.; Albert, J.; Avi, R.; Avila-Rios, S.; Bessong, P.O.; Brooks, J.I.; Boucher, C.A.B.; Brumme, Z.L.; Busch, M.P.; Bussmann, H.; Chaix, M.-L. ... Shafer, R.W. (2015). Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLoS Medicine, 12 (4), e1001810.10.1371/journal.pmed.1001810.
1.1.
2015
Nellis, Georgi; Metsvaht, Tuuli; Varendi, Heili; Toompere, Karolin; Lass, Jana; Mesek, Inge; Nunn, Anthony; Turner, Mark; Lutsar, Irja (2015). Potentially harmful excipients in neonatal medicines: a pan-European observational study. Archives of Disease in Childhood, 100 (7), 694−699. DOI: 10.1136/archdischild-2014-307793.
1.3.
2015
Parm, Ü.; Niitvägi, E.; Beljaev, K.; Aro, T.; Aotäht, E.; Raska, K.; Epštein, J.; Oona, M.; Lutsar, I. (2015). Puukborrelioos Saaremaal. Eesti Arst, 94 (4), 203−210.
3.1.
2015
Taba, P.; Lutsar, I. (2015). Chronic infectious inflammatory diseases of the central nervous system. In: Deisenhammer, F.; Sellebjerg, F.; Teunissen, C.E.; Tumani, H. (Ed.). Cerebrospinal Fluid in Clinical Neurology (211−245).. Springer.10.1007/978-3-319-01225-4_15.
5.2.
2015
Soeorg H, Huik K, Parm Ü, Ilmoja ML, Metsvaht T, Lutsar I. (2015). Molecular epidemiology of Staphylococcus epidermidis colonizing gastrointestinal tract of neonates hospitalized to intensive care unit. The 25th European Congress of Clinical Microbiology and Infectious Diseases, April 25-28, 2015, Copenhagen, Denmark..
5.2.
2015
Soeorg H, Metsvaht T, Eelmäe I, Merila M, Ilmoja ML, Lutsar I. (2015). Colonization of gastrointestinal tract (GIT) of preterm neonates with Staphylococcus epidermidis (SE) present in mother’s own unpasteurized breast milk (BM). The 33rd Annual Meeting of the European Society for Paediatric Infectious Diseases, May 12-16, 2015, Leipzig, Germany..
5.2.
2015
Nellis, Georgi; Varendi, Heili; Lutsar, Irja; Metsvaht, Tuuli (2015). Kõik Euroopa vastsündinutele manustatavad teadaolevate kõrvaltoimetega abiained ei ole hädavajalikud. Eesti Arst: TÜ Arstiteaduskonna aastapäeva teaduskonverents, Tartu, Eesti, 2015. , 12.
5.2.
2015
Nellis, Georgi; Lutsar, Irja; Varendi, Heili; Turner, Mark; Metsvaht, Tuuli (2015). Potentially harmful excipients in medicines prescribed in neonatal intensive care units (NICUs) – product substitution as a way forward. J Pediatr Neonat Individual Med: 1st Congress of joint European Neonatal Societies (jENS), Budapest, Hungary, 2015.
5.2.
2015
Rööp, Tiiu; Parm, Ülle; Metsvaht, Tuuli; Ilmoja, Mari-Liis; Lutsar, Irja; Mändar, Reet. (2015). Collection of antibiotic resistant microbes of neonatal origin in the Human Microbiota Biobank (HUMB) at the Department of Microbiology, University of Tartu. XXXIV ECCO meeting: European Culture Collections as tools in research and biotechnology, Institut Pasteur (CRBIP) in Paris, France, 27-29 May, 2015.
5.2.
2015
Jõgi, P.; Oona, M.; Lutsar, I. (2015). Pertussis epidemiology and clinical characteristics in Estonia. 3rd Baltic Paediatric Congress, Riga, Lativa, 19-21 August, 2015.
5.2.
2015
Jõgi, P.; Oona, M.; Toompere, K.; Lutsar, I. (2015). Estimated versus reported incidence of pertussis in Estonian adults. 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 25-28, 2015.
5.2.
2015
Jõgi, P.; Oona, M.; Epstein, J.; Lutsar, I. (2015). Epidemiology of pertussis in Estonian infants over the last 25 years. 33rd Annual Meeting of the European Society for Paediatric Infectious Diseases. Leipzig, Germany , May 12-16, 2015.
5.2.
2015
Kogermann, Karin; Putrinš, Marta; Lippus, Markus; Smidt, Imbi; Truusalu, Kai; Lutsar, Irja; Tenson, Tanel (2015). Bacterial phenotypic heterogeneity – single-cell level methods to study antimicrobial susceptibility during infection. In: . 6th BBBB Conference on Pharmaceutical Sciences, 10.-12.09.2015, Helsinki, Finland.
5.2.
2015
Kogermann, Karin; Putrins, Marta; Lippus, Markus; Smidt, Imbi; Truusalu, Kai; Lutsar, Irja; Tenson, Tanel (2015). Development of Escherichia coli systemic infection model for monitoring persisters and antibiotic susceptibility. In: . ECCMID 2015 Copenhagen, Denmark, 25-28 April 2015. ECCMID 2015 Copenhagen, Denmark, 25-28 April 2015.
5.2.
2015
Jõgeda, Ene-Ly; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Karki, Tõnis; Jarlais, Don Des; Uusküla, Anneli; Lutsar, Irja; Huik, Kristi; (2015). HTLV-1/2 is rare among Eastern-European intravenous drug users (IDUs). Retrovirology, 12, P79−P79. DOI: doi.org/10.1186/1742-4690-12-S1-P79.
5.2.
2015
Mesek, Inge; Nellis, Georgi; Metsvaht, Tuuli; Visk, Helle; Lass, Jana; Lutsar, Irja (2015). Regionaalsed erinevused Euroopas hospitaliseeritud vastsündinute ravimikasutuses. Tartu Ülikooli arstiteaduskonna aastapäeva teaduskonverents, Tartu, 8.-9. oktoober 2015.
5.2.
2015
Mesek, Inge; Nellis, Georgi; Lass, Jana; Lutsar, Irja (2015). Medication use in Neonatal Intensive Care Units across Europe. In: . European Society for Developmental Perinatal and Pediatric Pharmacology (ESDPPP), Belgrade, Serbia, 23.-26. June, 2015.
5.2.
2015
Mesek, Inge; Nellis, Georgi; Lass, Jana; Lutsar, Irja (2015). Medicines use at the European Neonatal Departments. In: . Nordic Social Pharmacy and Health Services Research Conference & Nordic Networking Group for Clinical Pharmacy Conference (NSPC&NNGCP), Tartu, 3.-5. June 2015.
6.8.
2015
Standing, Joseph F; Anderson, Brian J; Holford, Nicholas H G; Lutsar, Irja; Metsvaht, Tuuli (2015). Comment on Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design. Clinical Pharmacokinetics, 54 (12), 1287−1288. DOI: 10.1007/s40262-015-0344-5.
1.1.
2014
Huik, K.; Avi, R.; Uibopuu, H.; Pauskar, M.; Margus, T.; Karki, T.; Krispin, T.; Kool, P.; Rüütel, K.; Talu, A.; Abel-Ollo, K.; Uusküla, A.; Carrillo, AQ.; He, W.; Ahuja, SK.; Lutsar, I. (2014). Association between HIV-1 tropism and CCR5 human haplotype E in a Caucasian population. Jaids-Journal of Acquired Immune Deficiency Syndromes, 66 (3), 239−244. DOI: 10.1097/QAI.0000000000000127.
1.1.
2014
Lutsar, I.; Chazallon, C.; Carducci, FI.; Trafojer, U.; Abdelkader, B.; de Cabre, VM.; Esposito, S.; Giaquinto, C.; Heath, PT.; Ilmoja, ML.; Katragkou, A.; Lascoux, C.; Metsvaht, T.; Mitsiakos, G.; Netzer, E.; Pugni, L.; Roilides, E.; Saidi, Y.; Sarafidis, K.; Sharland, M. ... Aboulker, JP. (2014). Current management of late onset neonatal bacterial sepsis in five European countries. European Journal of Pediatrics, 173 (8), 997−1004.10.1007/s00431-014-2279-5.
1.1.
2014
Mitt, P.; Metsvaht, T.; Adamson, V.; Telling, K..; Naaber, P.; Lutsar, I.; Maimets , M. (2014). Five-year prospective surveillance of nosocomial bloodstream infections in an Estonian paediatric intensive care unit. Journal of Hospital Infection, 86 (2), 95−99. DOI: 10.1016/j.jhin.2013.11.002.
1.1.
2014
Turner, MA.; Duncan, JC.; Shah, U.; Metsvaht, T.; Varendi, H.; Nellis, G.; Lutsar, I.; Yakkundi, S.; McElnay, JC.; Pandya, H.; Mulla, H.; Vaconsin, P.; Storme, T.; Rieutord, A.; Nunn, AJ. (2014). Risk assessment of neonatal excipient exposure: Lessons from food safety and other areas. Advanced Drug Delivery Reviews, 73, 89−101. DOI: 10.1016/j.addr.2013.11.003.
1.1.
2014
Avi, R; Huik, K; Pauskar, M; Ustina, V; Karki, T; Kallas, E; Jõgeda, EL; Krispin, T; Lutsar, I (2014). Transmitted drug resistance is still low in newly diagnosed human immunodeficiency virus type 1 CRF06_cpx-infected patients in Estonia in 2010. Aids Research and Human Retroviruses, 30 (3), 278−283.10.1089/aid.2012.0357.
1.1.
2014
Simmons, R.; Lutsar, I.; Malyuta, R.; Rosińska, M.; Porter, K. (2014). Using incidence assays within the context of the recent infections testing algorithm. AIDS, 28 (14), 2167−2167.10.1097/QAD.0000000000000367.
1.1.
2014
Nellis, G.; Lutsar, I.; Varendi, H.; Toompere, K.; Turner, MA.; Duncan, J.; Metsvaht, T. (2014). Comparison of two alternative study designs in assessment of medicines utilisation in neonates. BMC Medical Research Methodology, 14, 89−94. DOI: 10.1186/1471-2288-14-89.
1.1.
2014
Lutsar, I.; Telling, K.; Metsvaht, T. (2014). Treatment option for sepsis in children in the era of antibiotic resistance. Expert Review of Anti-infective Therapy, 12 (10), 1237−1252.10.1586/14787210.2014.956093.
1.1.
2014
Jõgi, P.; Oona, M.; Toompere, K.; Leedo, S.; Epstein, J.; Lutsar, I (2014). Seroprevalence of IgG antibodies to pertussis toxin in children andadolescents in Estonia. Vaccine, 32 (41), 5311−5315. DOI: 10.1016/j.vaccine.2014.07.066.
1.1.
2014
Drell, Tiina; Lutsar, Irja; Štšepetova, Jelena; Parm, Ülle; Metsvaht, Tuuli; Ilmoja, Mari-Liis; Simm, Jaak; Sepp, Epp. (2014). The development of gut microbiota in critically ill extremely low birth weigth infants assessed with 16S rRNA gene based sequencing. Gut Microbes, 5, 1−7.
1.2.
2014
Toome, Liis; Plado, Silvi; Ringmets, Inge; Vals, Mari-Anne; Varendi, Heili; Lutsar, Irja (2014). Respiratory infections in very low gestational age infants: a population-based cohort study in Estonia. Journal of Pediatric and Neonatal Individualized Medicine, 3 (1), 1−10. DOI: 10.7363/030115.
3.5.
2014
Mesek, Inge; Nellis, Georgi; Lass, Jana; Lutsar, Irja (2014). Euroopa neonatoloogia osakondades kasutatavate ravimvormide vastsündinutele sobilikkuse hindamine kardiovaskulaarsüsteemi ravimite näitel. Eesti Arst: Tartu Ülikooli arstiteaduskonna aastapäeva teaduskonverents, Tartu, 9.-10. okt.
5.2.
2014
Soeorg H, Huik K, Parm Ü, Ilmoja ML, Metsvaht T, Lutsar I. (2014). Vancomycin-heteroresistance in Staphylococcus epidermidis colonizing neonates in neonatal intensive care units. The 32nd Annual Meeting of the European Society for Paediatric Infectious Diseases, May 6-10, 2014, Dublin, Ireland..
5.2.
2014
Jõgi, P.; Oona, M.; Toompere, K.; Epstein, J.; Lutsar, I. (2014). Does the number of boosters and the diagnostic method influence the notification of pertussis? 32th Annual Meeting of the European Society for Paediatric Infectious Diseases. Dublin, Ireland, May 6-10..
5.2.
2014
Kogermann, K.; Putrinś, M.; Lippus, M.; Smidt, I.; Truusalu, K.; Lutsar, I.; Tenson, T. (2014). Monitoring bacterial persisters during E.coli infection development in mouse model. In: . CBM2014, Tartu, Estonia, 16.-19.10.2014.
1.1.
2013
Oeser, C; Lutsar, I; Metsvaht, T; Turner, MA; Heath, PT; Sharland, M (2013). Clinical trials in neonatal sepsis. Journal of Antimicrobial Chemotherapy, 68 (12), 2733−2745. DOI: 10.1093/jac/dkt297.
1.1.
2013
Garazzino, S; Lutsar, I; Bertaina, C; Tovo, PA; Sharland, M (2013). New antibiotics for paediatric use: A review of a decade of regulatory trials submitted to the European Medicines Agency from 2000-Why aren't we doing better? International Journal of Antimicrobial Agents, 42 (2), 99−118. DOI: 10.1016/j.ijantimicag.2013.05.001.
1.1.
2013
Soeorg, H.; Huik, K.; Parm, U.; Ilmoja, ML.; Metelskaja, N.; Metsvaht, T.; Lutsar, I. (2013). Genetic Relatedness of Coagulase-Negative Staphylococci from Gastrointestinal Tract and Blood of Preterm Neonates with Late-Onset Sepsis. The Pediatric Infectious Disease Journal, 32 (4), 389−393.10.1097/INF.0b013e3182791abd.
1.1.
2013
Quinlivan, M.; Sengupta, N.; Papaevangelou, V.; Sauerbrei, A.; Grillner, L.; Rousseva, R.; Hague, R.; Lutsar, I.; Jogi, P.; Leca, A.; Grytchol, R.; Alain, S.; Breuer, J. (2013). Use of oral fluid to examine the molecular epidemiology of varicella zoster virus in the United kingdom and continental europe. The Journal of Infectious Diseases, 207 (4), 588−593. DOI: 10.1093/infdis/jis649.
1.1.
2013
Turner, Mark; Duncan, Jennifer; Shah, Utpal; Metsvaht, Tuuli; Varendi, Heili, Nellis, Georgi; Lutsar, Irja; Vaconsin, Pascal; Storme, Thomas; Rieutord, Andre; Nunn, Anthony (2013). European Study of Neonatal Exposure to Excipients: An update. International Journal of Pharmaceutics, 457 (1), 357−358. DOI: 10.1016/j.ijpharm.2013.08.078.
1.1.
2013
Lodi, S; del Amo, J; d'Arminio Monforte, A; Abgrall, S; Sabin, C; Morrison, C; Furrer, H; Muga, R; Porter, K; Girardi, E (2013). Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax, 68 (3), 207−213.10.1136/thoraxjnl-2012-201740.
1.1.
2013
Touloumi, G; Pantazis, N; Pillay, D; Paraskevis, D; Chaix, ML; Bucher, HC; Kucherer, C; Zangerle, R; Kran, AM; Porter, K (2013). Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. Clinical Infectious Diseases, 56 (6), 888−897. DOI: 10.1093/cid/cis1000.
1.1.
2013
van der Helm, J; Geskus, R; Sabin, C; Meyer, L; Del Amo, J; Chene, G; Dorrucci, M; Muga, R; Porter, K; Prins, M (2013). Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after. Gastroenterology, 144 (4), 751−760.10.1053/j.gastro.2012.12.026.
1.1.
2013
Rosinska, M; Marzec-Bogustawska, A; Janiec, J; Smolen-Dzirba, J; Wasik, T; Gniewosz, J; Zalewska, M; Murphy, G; McKinney, E; Porter, K (2013). High percentage of recent HIV infection among HIV-positive individuals newly diagnosed at voluntary counseling and testing sites in Poland. Aids Research and Human Retroviruses, 29 (5), 805−813.10.1089/aid.2012.0314.
1.1.
2013
Madec, Y; Boufassa, F; Porter, K; Prins, M; Sabin, C; d'Arminio Monforte, A; Amornkul, P; Bartmeyer, B; Sannes, M; Venet, A; Lambotte, O; Meyer, L (2013). Natural history of HIV-control since seroconversion. AIDS, 27 (15), 2451−2460.10.1097/01.aids.0000431945.72365.01.
1.1.
2013
Lodi, S; Fisher, M; Phillips, A; De Luca, A; Ghosn, J; Malyuta, R; Zangerle, R; Moreno, S; Vanhems, P; Boufassa, F; Guiguet, M; Porter, K (2013). Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection. PLoS ONE, 8 (11), e78642.10.1371/journal.pone.0078642.
1.1.
2013
Versporten, A.; Sharland, M.; Bielicki, J.; Drapier, N.; Vankerckhoven, V.; Goossens, H.; ARPEC, Project Group Members (incl. Lutsar I). (2013). The antibiotic resistance and prescribing in European Children project: a neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide. The Pediatric Infectious Disease Journal, 32 (6), e242−e253.10.1097/INF.0b013e318286c612.
1.1.
2013
Brilene, T.; Soeorg, H.; Kiis, M.; Sepp, E.; Kõljalg, S.; Lõivukene, K.; Jürna-Ellam, M.; Kalinina, J.; Stšepetova, J.; Metsvaht, T.; Lutsar, I. (2013). In vitro synergy of oxacillin and gentamicin against coagulase-negative staphylococci from blood cultures of neonates with late-onset sepsis. Apmis, 121 (9), 859−864. DOI: 10.1111/apm.12048.
1.1.
2013
Huik, K; Avi, R; Pauskar, M; Kallas, E; Jõgeda, EL; Karki, T; Marsh, K; Des Jarlais, D; Uusküla, A; Lutsar, I (2013). Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users. Infection Genetics and Evolution, 20, 78−82.10.1016/j.meegid.2013.08.008.
1.1.
2013
Huik, K; Avi, R; Carrillo, A; Harper, N; Pauskar, M; Sadam, M; Karki, T; Krispin, T; He, W; Lutsar, I (2013). CCR5 Haplotypes Influence HCV Serostatus in Caucasian Intravenous Drug Users. PLoS ONE, 8 (7), e70561. DOI: 10.1371/journal.pone.0070561.
1.2.
2013
Standing, JF; Tsolia, M; Lutsar, I (2013). Pharmacokinetics and pharmacodynamics of oseltamivir in neonates, infants and children. Infectious Disorders - Drug Targets, 13 (1), 6−14.
1.2.
2013
Lass, J.; Odlind, V.; Irs, A.; Lutsar, I. (2013). Antibiotic prescription preferences in paediatric outpatient setting in Estonia and Sweden. SpringerPlus, 2, 124−x.10.1186/2193-1801-2-124.
1.2.
2013
Lill, M.; Kõks, S.; Soomets, U.; Schalkwyk, LC.; Fernandes, C.; Lutsar, I.; Taba, P. (2013). Peripheral blood RNA gene expression profiling in patients with bacterial meningitis. Frontiers in Neuroscience, 7, 33.10.3389/fnins.2013.00033.
5.2.
2013
Turner, M.; Yakkundi, S.; Varendi, H.; Metsvaht, T.; Nellis, G.; Windrow, J.; Graham, S.; Mulla, H.; Pandya, H.; Tapscott, S.; Caldwell, N.; Duncan, J.; Lutsar, I.; McElnay, J. (2013). Methyl and propyl paraben concentrations in blood from preterm neonates exposed to clinically indicated medicines are lower than the concentrations of these anti-microbial excipients reported to affect cell physiology. 14th Biannual Congress of the European Society for Developmental Perinatal and Pediatric Pharmacology (EDPPP), Salzburg, Austria, 04.-07.06.2013.
5.2.
2013
Nellis, G.; Metsvaht, T.; Lass, J.; Varendi, H.; Turner, M.; Lutsar, I. (2013). European Study of Neonatal Excipient Exposure (ESNEE): preliminary results of the point prevalence survey. 14th Biannual Congress of the European Society for Developmental Perinatal and Pediatric Pharmacology (EDPPP), Salzburg, Austria, 04.-07.06.2013.
1.1.
2012
Jarrin, I; Pantazis, N; Gill, MJ; Geskus, R; Perez-Hoyos, S; Meyer, L; Prins, M; Touloumi, G; Johnson, A; Hamouda, O; de Olalla, PG; Porter, K; del Amo, J (2012). Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clinical Infectious Diseases, 54 (1), 111−118. DOI: 10.1093/cid/cir814.
1.1.
2012
Pulcini, C; Bush, K; Craig, WA; Frimodt-Moller, N; Grayson, ML; Mouton, JW; Turnidge, J; Harbarth, S; Gyssens, IC (2012). Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clinical Infectious Diseases, 54 (2), 268−274. DOI: 10.1093/cid/cir838.
1.1.
2012
Pantazis, N; Morrison, C; Amornkul, PN; Lewden, C; Salata, RA; Minga, A; Chipato, T; Jaffe, H; Lakhi, S; Karita, E; Porter, K; Meyer, L; Touloumi, G (2012). Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS ONE, 7 (3), e32369.10.1371/journal.pone.0032369.
1.1.
2012
Zugna, D; Geskus, RB; De Stavola, B; Rosinska, M; Bartmeyer, B; Boufassa, F; Chaix, ML; Babiker, A; Porter, K (2012). Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection. Antivir Ther 17:1039-1048. Antiviral Therapy, 17 (6), 1039−1048.10.3851/IMP2312.
1.1.
2012
Huang, X.; Lodi, S.; Fox, Z.; Li, W.; Phillips, A.; Porter, K.; Lutsar, I.; Kelleher, A.; Li, N.; Xu, X.; Wu, H.; Johnson, AM. (2012). Rate of CD4 decline and HIV-RNA change following HIV Seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. Jaids-Journal of Acquired Immune Deficiency Syndromes, 62 (4), 441−446.10.1097/QAI.0b013e31827f5c9a.
1.1.
2012
Lass, J.; Naelapää, K.; Shah, U.; Käär, R.; Varendi, H.; Turner, MA.; Lutsar, I. (2012). Hospitalised neonates in Estonia commonly receive potentially harmful excipients. BMC Pediatrics, 12, 136.10.1186/1471-2431-12-136.
1.1.
2012
Padari, H.; Metsvaht, T.; Kõrgvee, LT.; Germovsek, E.; Ilmoja, ML.; Kipper, K.; Herodes, K.; Standing, JF.; Oselin, K.; Lutsar, I. (2012). Short versus Long Infusion of Meropenem in Very-Low-Birth-Weight Neonates. Antimicrobial Agents and Chemotherapy, 56 (9), 4760−4764.10.1128/AAC.00655-12.
1.1.
2012
Esposito, S.; Cohen, R.; Domingo, JD.; Pecurariu, OF.; Greenberg, D.; Heininger, U.; Knuf, M.; Lutsar, I.; et, al. (2012). Antibiotic Therapy for Pediatric Community-Acquired Pneumonia: Do We Know When, What and For How Long to Treat? The Pediatric Infectious Disease Journal, 31 (6), e78−e85.10.1097/INF.0b013e318255dc5b.
1.1.
2012
Soeorg, H.; Tamm, E.; Huik, K.; Pauskar, M.; Mägi, D.; Pruudel, K.; Vainomäe, L.; Moosar, L.; Kirss, K.; Torm, S.; Närska, M.; Pütsepp, A.; Nurm, H.; Pruunsild, K.; Jänes, A.; Zilmer, K.; Lutsar, I. (2012). Group A rotavirus genotypes circulating prior to implementation of a National Immunization Program in Estonia. Human Vaccines, 8 (4), 465−469.10.4161/hv.19135.
1.2.
2012
Tamme, Kadri; Minajeva, Ave;, Adamson, Vivika; Ristmägi, Kaarina; Põder, Jaak; Lutsar, Irja (2012). Clinical Findings and Pathologic Changes Associated with Fatal Cases of 2009/2010 Pandemic Influenza A/H1N1 Viral Infection in Estonia. A Retrospective Study. Medicina (Kaunas), 48 (1), 48−56.
1.3.
2012
Jõgi, P.; Oona, M.; Tamm, E.; Lutsar, I. (2012). Läkaköha nüüdisaegne diagnostika. Eesti Arst, 91 (1), 19−25.
1.3.
2012
Prükk, T.; Maimets, M.; lutsar, I. (2012). Lyme’i tõve nüüdisaegne diagnostika ja ravi. Eesti Arst, 91 (2), 141−147.
5.2.
2012
Lass, Jana; Metsvaht, Tuuli; Nellis, Georgi; Lutsar, Irja (2012). The comparability of different study methodologies for evaluating antibiotic consumption in neonatal intensive care units (NICU). ESPID.
5.2.
2012
Nellis, Georgi; Varendi, Heili; Lass, Jana; Lutsar, Irja; Metsvaht, Tuuli. (2012). Antibiotic prescribing in European neonatal intensive care units: service evaluation study of the European study of neonatal exposure to excipients. Eesti Arst: TÜ Arstiteaduskonna päev, okt.2012. , 11. (91).
5.2.
2012
Nellis, Georgi; Varendi, Heili; Lass, Jana; Lutsar, Irja; Metsvaht, Tuuli. (2012). Potentially Harmful Excipients in Antibiotics Prescribed to European Neonates - ESNEE Survey. Acta Médica Portuguesa: 3rd International Congress of UENPS, 2012; Porto, nov 14-17. , 141. (25; 2).
5.2.
2012
Varendi, Heili; Nellis, Georgi; Metsvaht, Tuuli; Lass, Jana; Lutsar, Irja. (2012). European Study of the Neonatal Exposure to Excipients: Results of the Survey, Enterally Administered Products. Acta Médica Portuguesa : 3rd International Congress of UENPS 2012; Porto, nov 14-17. Portugal, 141−142. (25; S2).
1.1.
2011
Yakkundi, Shirish; McElnay, James; Millership, Jeff; Mulla, Hussain; Pandya, Hitesh; Shah, Utpal; Nunn, Tony; Rieutord, Andre; Storme, Thomas; Vasconsin, Pascal; Metsvaht, Tuuli; Varendi, Heili; Nellis, Georgi; Lutsar, Irja; Turner, Mark. (2011). Use of dried blood spots to study excipient kinetics in neonates. Bioanalysis, 3 (24), 2691−2693. DOI: 10.4155/BIO.11.277.
1.1.
2011
Lutsar, I.; Trafojer, UM.; Heath, PT.; Metsvaht, T.; Standing, J.; Esposito, S.; de Cabre, VM.; Oeser, C.; Aboulker, JP. (2011). Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial. Trials, 12, 215.10.1186/1745-6215-12-215.
1.1.
2011
Metsvaht, T.; Ilmoja, ML.; Parm, U.; Merila, M.; Maipuu, L.; Müürsepp, P.; Julge, K.; Sepp, E.; Lutsar, I. (2011). Ampicillin versus penicillin in the empiric therapy of ELBW neonates at risk of early onset sepsis. Pediatrics International, 5 (53), 873−880.
1.1.
2011
Freire-Moran, L.; Aronsson, B.; Manz, C.; Gyssens, IC.; So, AD.; Monnet, DL.; Cars, O.; ECDC-EMA Working Group (incl. Lutsar, I.) (2011). Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. Drug Resistance Updates, 14, 118−124.
1.1.
2011
Parm, U.; Metsvaht, T.; Sepp, E.; Ilmoja, ML.; Pisarev, H.; Pauskar, M.; Lutsar, I. (2011). Mucosal surveillance cultures in predicting Gram-negative late-onset sepsis in neonatal intensive care units. Journal of Hospital Infection, 78 (4), 327−332. DOI: 10.1016/j.jhin.2011.03.025.
1.1.
2011
Lass, Jana; Käär, Ruth; Jõgi, Kaarin; Varendi, Heili; Metsvaht, Tuuli; Lutsar, Irja (2011). Drug utilisation pattern and off-label use of medicines in Estonian neonatal units. European Journal of Clinical Pharmacology, 12 (67), 1263-1271−1271. DOI: 10.1007/s00228-011-1072-x.
1.1.
2011
Mussini, C; Cossarizza, A; Sabin, C; Babiker, A; De Luca, A; Bucher, HC; Fisher, M; Rezza, G; Porter, K; Dorrucci, M (2011). Decline of CD4(+) T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals. AIDS, 25 (8), 1041−1049.10.1097/QAD.0b013e3283463ec5.
1.1.
2011
van der Helm, JJ; Prins, M; del Amo, J; Bucher, HC; Chene, G; Dorrucci, M; Gill, J; Hamouda, O; Sannes, M; Porter, K; Geskus, RB (2011). The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS, 25 (8), 1083−1091.10.1097/QAD.0b013e3283471cce.
1.1.
2011
Jaffe, HW; De Stavola, BL; Carpenter, LM; Porter, K; Cox, DR (2011). Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. AIDS, 25 (11), 1395−1403.10.1097/QAD.0b013e3283489c8b.
1.1.
2011
Lutsar, Irja (2011). Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Archives of Internal Medicine, 171 (17), 1560−1569. DOI: 10.1001/archinternmed.2011.401.
1.1.
2011
Parm, U.; Metsvaht, T.; Sepp, E.; Ilmoja, ML.; Pisarev, H.; Pauskar, M.; Lutsar, I. (2011). Risk factors associated with gut and nasopharyngeal colonization by common Gram-negative species and yeasts in neonatal intensive unit patients. Early Human Development, 87 (6), 391−399.10.1016/j.earlhumdev.2011.02.007.
1.1.
2011
Lass, J.; Irs, A.; Pisarev, H.; Leinemann, T.; Lutsar, I. (2011). Off label use of prescription medicines in children in outpatient setting in Estonia is common. Pharmacoepidemiology and Drug Safety, 20 (5), 474−481.10.1002/pds.2125.
1.1.
2011
Heidmets, LT.; Metsvaht, T.; Ilmoja, ML.; Pisarev, H.; Oselin, K.; Lutsar, I. (2011). Blood Loss Related to Participation in Pharmacokinetic Study in Preterm Neonates. Neonatology, 100 (2), 111−115.
1.1.
2011
Avi, R; Huik, K; Pauskar, M; Ustina, V; Karki, T; Krispin, T; Ainsalu, K; Paap, P; Schmidt, J; Nikitina, N; Lutsar, I. (2011). Emerging Transmitted Drug Resistance in Treatment Naive Human Immunodeficiency Virus - 1 CRF06_cpx Infected Patients in Estonia. Scandinavian Journal of Infectious Diseases, 43 (2), 122−128.
1.2.
2011
Knellwolf, A.L.; Bauzon, S.; Della Casa Alberighi, O.; Lutsar, I.; Bacsy, E.; Alfarez, D.; Panei, P. (2011). Framework conditions facilitating paediatric clinical research. Italian Journal of Pediatrics, 37, 12. DOI: 10.1186/1824-7288-37-12.
1.3.
2011
Müürsepp, P.; Kõivumägi, K.; Kumm, ML.; Zilmer, K.; Lutsar, I. (2011). Tuulerõuged laste ja noorukite hospitaliseerimise põhjusena Eestis aastatel 2000–2005. Eesti Arst, 91 (1), 27−32.
5.1.
2011
Lill, M.; Lutsar, I.; Taba, P. (2011). Community-acquired bacterial meningitis in Estonia 2008-2009. EUROPEAN JOURNAL OF NEUROLOGY, 18: 15th Congress of the European-Federation-of-Neurological-Societies (EFNS) Location: Budapest, HUNGARY Date: SEP 10-13, 2011. 476. (SI 2).
5.2.
2011
Standing, J.; Morris, J.; Germovsek, E.; Lutsar, I.; Cortina-Borja, M. (2011). Methods for Optimising Neonatal Antimicrobial Use: Time- and Concentration-Dependent Agents. Page Conference, Athens 2011.
1.1.
2010
Wolbers, M; Babiker, A; Sabin, C; Young, J; Dorrucci, M; Chene, G; Mussini, C; Porter, K; Bucher, HC (2010). Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies. PLoS Medicine, 7 (2), e1000239.10.1371/journal.pmed.1000239.
1.1.
2010
Walsh, T.J.; Driscoll, T.; Milligan, P.A.; Wood, N.D.; Schlamm, H.; Groll, A.H.; Jafri, H.; Arrieta, A.C.; Klein, N.J.; Lutsar, I. (2010). Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrobial Agents and Chemotherapy, 54 (10), 4116−4123.10.1128/AAC.00896-10.
1.1.
2010
Parm, Ü.; Metsvaht, T.; Sepp, E.; Ilmoja, ML.; Pisarev, H.; Pauskar, M.; Lutsar, I. (2010). Impact of empiric antibiotic regimen on bowel colonization in neonates with suspected early onset sepsis. European Journal of Clinical Microbiology & Infectious Diseases, 29 (7), 807−816. DOI: 10.1007/s10096-010-0931-1.
1.1.
2010
Avi, R.; Huik, K.; Sadam, M.; Karki, T.; Krispin, T.; Ainsalu, K.; Paap, P.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2010). Characterization of Integrase Region Polymorphisms in HIV-1 CRF06_cpx Viruses in Treatment Naïve Patients in Estonia. Aids Research and Human Retroviruses, 26 (10), 1109−1113.10.1089/aid.2010.0097.
1.1.
2010
Lutsar, I.; Metsvaht, T. (2010). Understanding pharmacokinetic/pharmacodynamic in managing neonatal sepsis. Current Opinion in Infectious Diseases, 23 (3), 201−207.
1.1.
2010
Metsvaht, T.; Ilmoja, ML.; Parm, Ü.; Maipuu, L.; Merila, M.; Lutsar, I. (2010). Comparison of ampicillin plus gentamicin vs. penicillin plus gentamicin in empiric treatment of neonates at risk of early onset sepsis. Acta Paediatrica, 99 (5), 665−672.10.1111/j.1651-2227.2010.01687.x.
1.1.
2010
Huik, K.; Sadam, M.; Karki, T.; Avi, R.; Krispin, T.; Paap, P.; Rüütel, K.; Uusküla, A.; Talu, A.; Abel-Ollo, K.; Lutsar, I. (2010). CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users. The Journal of Infectious Diseases, 730−739.
3.2.
2010
Lutsar, I; Friedland, I. (2010). Clinical Trials of Anti-Infective Agents in Paediatrics. In: Rose, Klaus; van den Anker, John N. (Ed.). Guide to Paediatric Drug Development (170−177). . Basel, Switzerland: Karger. DOI: 10.1159/000315588.
5.2.
2010
Lill, M.; Kõks, S.; Soomets, U.; Schalkwyk, LC.; Fernandes, C.; Lutsar, I., Taba, P. (2010). Peripheral blood RNA gene expression profiling in the patients with community-acquired bacterial meningitis. In: (x).20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 10 - 13 April.
1.1.
2009
Brown, AE.; Gifford, RJ.; Clewley, JP.; Kucherer, C.; Masquelier, B.; Porter, K.; Balotta, C.; Back, NK.; Jorgensen, LB.; de Mendoza, C.; Bhaskaran, K.; Gill, ON.; Johnson, AM.; Pillay, D.; CASCADE Collaboration including Lutsar, I. (2009). Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions. The Journal of Infectious Diseases, 199 (3), 427−431.
1.1.
2009
Prymula, R; Anca, I; André, F; Bakir, M; Czajka, H; Lutsar, I; Mészner, Z; Salman, N; Simurka, P; Usonis, V. (2009). Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines. European Journal of Pediatrics, 168, 1031−1035.
1.1.
2009
Avi, R; Huik, K; Sadam, M; Karki, T; Krispin, T; Ainsalu, K; Paap, P; Schmidt, J; Nikitina, N; Lutsar, I. (2009). Absence of Genotypic Drug Resistance and Presence of Several Naturally Occurring Polymorphisms of Human Immunodeficiency Virus-1 CRF06_cpx in Treatment-Naive Patients in Estonia. Journal of Medical Virology, 81 (6), 953−958. DOI: 10.1002/jmv.21482.
1.1.
2009
Karlsson, MO.; Lutsar, I.; Milligan, PA. (2009). A population pharmacokinetic of voriconazole plasma concentration data from pediatric studies. Antimicrobial Agents and Chemotherapy, 53 (3), 935−944. DOI: 10.1128/AAC.00751-08.
1.1.
2009
Lutsar, I.; Anca, I.; Bakir, M.; Usonis, V.; Prymula, R.; Salman, N.; Grezesiowski, P.; Greenberg, M. (2009). Epidemiological characteristics of pertussis in Estonia, Lithuania, Romania, the Czech Republic, Poland and Turkey-1945 to 2005. European Journal of Pediatrics, 168, 407−415. DOI: 10.1007/s00431-008-0754-6.
1.1.
2009
Metsvaht, T.; Pisarev, H.; Ilmoja, ML.; Parm, U.; Maipuu, L.; Merila, M.; Muursepp, P.; Lutsar, I. (2009). Clinical parameters predicting failure of empirical antibacterial therapy in early onset neonatal sepsis, identified by classification and regression tree analysis. BMC Pediatrics, 9, 72. DOI: 10.1186/1471-2431-9-72.
1.3.
2009
Lutsar, I.; Metsvaht, T.; Tamm, E. (2009). Meningokokiline infektsioon lastel ja täiskasvanutel. Eesti Arst, 88 (1), 28−40.
5.2.
2009
Huik, K.; Avi, R.; Sadam, M.; Karki, T.; Denks, K.; Krispin, T.; Ustina, V.; Rüütel, K.; Uusküla, A.; Murphy, G.; Lutsar, I. (2009). Performance of the BED-CEIA in population infected with HIV1 recombinant viruses CRF06cpx and CRF06A. Clinical Microbiology and Infection: 19th European Congress of Clinical Microbiology and Infectious Diseases Helsinki, Finland, 16 - 19 May 2009.
6.3.
2009
Lutsar Irja, Lass Jana (2009). Ravimite kasutamine lastel. Lege Artis, 5, 42−45.
1.1.
2008
Jarrin, I.; Geskus, R.; Bhaskaran, K.; Prins, M.; Perez-Hoyos, S.; Muga, R.; Hernández-Aguado, I.; Meyer, L.; Porter, K.; del Amo, J.; Group author CASCADE Collaboration, (incl. I.Lutsar). (2008). Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. American Journal of Epidemiology, 168 (5), 532−540. DOI: 10.1093/aje/kwn179.
1.1.
2008
Bhaskarran, K.; Hamouda, O.; Sannes, M.; Bonfassa, F.; Johnson, A.M.; Lambert, P.C.; Porter, K.; CASCADE, Collaboration (2008). Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population. JAMA : the journal of the American Medical Association, 300 (1), 51−59.
1.1.
2008
Touloumi, G.; Pantazis, N.; Stirnadel, HA.; Walker, AS.; Boufassa, F.; Vanhems, P.; Porter, K.; Cascade including Lutsar, I. (2008). Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice. Jaids-Journal of Acquired Immune Deficiency Syndromes, 49 (5), 492−498.
1.1.
2008
Pantazis, N.; Touloumi, G.; Vanhems, P.; Gill, J.; Buchere, HC.; Porter, K.; CASCADE Collaboration (incl. Lutsar, I.) (2008). The effect of antiretroviral treatment of different durations in primary HIV infection. AIDS, 22 (18), 2441−2450. DOI: 10.1097/QAD.0b013e328319ea4e.
1.1.
2008
Meriste, S.; Jacquet, J.-M.; Willems, P.; Lutsar, I. (2008). Immunologic response to Hib tetanus toxoid conjugated vaccine coadministered with DTPa either mixed or in two separate injections in toddlers not primed with Hib vaccine. Human Vaccines, 4 (1), 31−35.
1.1.
2008
Troke, P.; Aguirrebengoa, K.; Arteaga, C.; Ellis, D.; Heath, C.; Lutsar, I.; Rovira, M.; Nguyen, Q.; Slavin, M.; Chen, S. (2008). Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients. Antimicrobial Agents and Chemotherapy, 52 (5), 1743−1750.
5.2.
2008
Uudelepp, ML.; Tamm, E.; Torm, S.; Urbsoo, K.; Pruunsild, K.; Part, R.; Lutsar, I. (2008). Bacterial meningitis in children in Estonia in 1980-1989 and 1998-2007. 17th ESPID; Graz, Austria; 13-17 May 2008.
5.2.
2008
Merila, M.; Metsvaht, T.; Parm, Ü.; Maipuu, L.; Müürsepp, P.; Lutsar, I. (2008). Maternal risk-factors of need for early change of empirical antibacterial treatment in neonates with high risk of sepsis. In: . 26th ESPID; Graz, Austria; 13-17 May 2008.
5.2.
2008
Eimra, K.; Parm, Ü.; Metsvaht, T.; Ilmoja, ML.; Lutsar, I. (2008). Genotypic Relatedness of Candida spp. in Two NICU-s in Estonia. 26. European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 19-22 Apr 2008.
5.2.
2008
Parm, Ü.; Sepp, E.; Metsvaht, T.; Ilmoja, ML.; Pruunsild, K.; Maipuu, L.; Kõljag, S.; Makoid, E.; Lutsar, I. (2008). The association between mucosal colonisation with opportunistic pathogens and blood stream infections in the two NICUs in Estonia. 26. European Congress of Clinical Microbiology and Infectious Diseases; Barcelona; 19-22 Apr 2008.
5.2.
2008
Metsvaht, T.; Ilmoja, M.-L.; Parm, Ü.; Merila, M.; Maipuu, L.; Sepp, E.; Müürsepp, P.; Lutsar, I. (2008). Management of Early Onset Neonatal Sepsis (EOS): comparative study of ampicillin (AMP) vs penicillin (PEN) in combination with gentamicin (GEN). International Conference of Antimicrobial Agents and Chemotherapy; Washington; 24-28 Oct 2008.
5.2.
2008
Truusalu, K.; Kõljalg, S.; Parm, Ü.; Sepp, E.; Metsvaht, T.; Naaber, P.; Lõivukene, K.; Lutsar, I. (2008). Staphylococcal Infection and Colonization of Pediatric Intensive Care Unit Patients: MRSA versus MRSE. Abstract book: Emerging Technologies of Medical Importance for the Diagnosis of Infectious Diseases and the Detection of Pathogenic Microbes. 1 st Intenational ASM Conference in Bejing, April 6-10, 2008. , 44.
5.2.
2008
Mitt, P.; Adamson, V.; Truusalu, K.; Parm, Ü.; Kõljalg, S.; Sepp, E.; Lõivukene, K.; Lutsar, I.; Maimets, M. (2008). An outbreak of meticillin-resistant Staphylococcus aureus (spa type t008) in the paediatric intensive care unit of a university hospital, Tartu. Clinical Microbiology and Infection, 14: 18th European Congress of Clinical Microbiology and Infectious Diseases. , Abstract number: P1439. (S7).
5.2.
2008
Huik, K.; Avi, R.; Sadam, M.; Karki, T.; Albert, J.; Lutsar, I. (2008). Drug Resistance Mutations in HIV-1 CRF06_cpx Viruses Isolated from Treatment Naïve and Experienced Patients. European Journal of Medical Research: 19th European Students’ Conference; Berlin; 28 September - 3 October 2008.
5.2.
2008
Avi, R.; Huik, K.; Karki, T.; Sadam, M.; Krispin, T.; Ainsalu, K.; Paap, P.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2008). Drug Resistance Mutations and Genetic Barrier for Drug Resistance Development in Estonian HIV-1 CRF06_cpx Integrase Sequences. 14th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology; Cape Town, South Africa; 1-5 September 2008.
5.2.
2008
Avi, R.; Huik, K.; Sadam, M.; Karki, T.; Krispin, T.; Paap, P.; Ainsalu, K.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2008). Natural polymorphisms associated with integrase inhibitor drug resistance in Estonian HIV-1 CRF06_cpx strains. 18th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona; 19.04-22.04.2008.
5.2.
2008
Sadam, M.; Karki, T.; Huik, K.; Avi, R.; Rüütel, K.; Uusküla, A.; Lutsar, I (2008). CCL3L1 Variable Gene Copy Number Influence on the Susceptibility to HIV-1/AIDS Among Estonian Intravenous Drug User. The 15th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, 03.02-06.02.2008.
1.1.
2007
Tamm, E.; Naaber, P.; Maimets, M.; Oona, M.; Kõljalg, S.; Lutsar, I. (2007). Antimicrobial susceptibility and serogroup/serotype distribution of nasopharyngeal isolates of Streptococcus pneumoniae in healthy Estonian children in 1999-2003. Clinical Microbiology and Infection, 13 (8), 824−826. DOI: 10.1111/j.1469-0691.2007.01743.x.
1.1.
2007
Metsvaht, T.; Oselin, K.; Ilmoja, M.; Anier, K.; Lutsar, I. (2007). Pharmacokinetics of penicillin G in very-low-birth-weight neonates. Antimicrobial Agents and Chemotherapy, 51 (6), 1995−2000.
1.3.
2007
Sergejev, M.; Lutsar, I. (2007). Gripivastased ravimid. Eesti Arst, 86 (2), 82−84.
5.1.
2007
Denks, K.; Huik, K.; Avi, R.; Sadam, M.; Krispin, T.; Lutsar, I. (2007). GB virus C infection among HIV-positive patients in Estonia. International Journal of Antimicrobial Agents, 29 (3), S155−S155.
5.1.
2007
Avi, R.; Huik, K.; Karki, T.; Sadam, M.; Paap, P.; Smidt, J.; Ainsalu, K.; Krispin, T.; Lutsar, I (2007). The coexistence of secondary PR mutations M36I, K20I and L63H predominates in CRF06_cpx and its next generation recombinant virusese circulating in Estonian treatment naive patients. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 29. S549−S549.
5.2.
2007
Parm, Ü., Sepp, E., Metsvaht, T., Ilmoja, M.L.., Lutsar, I. (2007). Oportunistlike mikroobide esinemine intensiivravi osakonnas viibivatel vastsündinutel. Eesti Arst, 86: Õppejõudude, teadurite, doktorantide, magistrantide ja üliõpilaste teaduskonverents 18. oktoobril 2007 TÜ Biomeedikumis. Eesti Arst, 673. (9).
6.2.
2007
Lutsar, I.; Mikelsaar, M.; Karki, T. (2007). Meditsiiniline mikrobioloogia II. Tartu: Tartu Ülikooli Kirjastus.
1.1.
2006
Meriste, S.; Lutsar, I.; Tamm, E.; Willems, P. (2006). Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine. Scandinavian Journal of Infectious Diseases, 38 (5), 350−356.
1.3.
2006
Meriste, S.; Oona, M.; Tamm, E.; Lutsar, I. (2006). Immuniseerimisega välditavate nakkushaiguste levik ja preventsioon Euroopas ja Eestis. Eesti Arst, 85 (2), 107−126.
6.2.
2006
Mikelsaar, M.; Karki, T.; Lutsar, I.; Mändar, R. (2006). Meditsiiniline mikrobioloogia I. Tartu: Tartu Ülikooli Kirjastus.
1.1.
2005
Mouas, H.; Lutsar, I.; Dupont, B.; Fain, O.; Herbrecht, R.; Lescure, F.; Lorthorlary, O. (2005). Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clinical Infectious Diseases, 40 (8), 1141−1147.
1.1.
2005
Usonis, V.; Meriste, S.; Bakasenas, V.; Lutsar, I.; Collard, F.; Stoffeld, A.; Tornieporth, N. (2005). Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months. Vaccine, 23 (20), 2602−2606.
1.1.
2005
Schwartz, S.; Ruhnke, M.; Ribaud, P.; Corey, L.; Driscoll, T.; Cornely, OA.; Schuler, U.; Lutsar, I.; Troke, P.; Thiel, E. (2005). Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood, 106 (8), 2641−2645.
1.3.
2005
Lutsar, I. (2005). HI-viirusinfektsioon kui globaalne probleem. Eesti Arst, 4, 238−243.
3.3.
2005
Lutsar, I.; Tamm, E.; Metsvaht, T.; Roos, R. (2005). Antimikroobsete ravimite manustamine lastele. Tallinn: Medicina.
5.2.
2005
Roos, R.; Adamson, V.; Lutsar, I.; Metsvaht, T. (2005). Antibiootikumide (AB) tarbimise ja koormuse hindamine TÜ Kliinikumi lasteintensiivravi osakonnas: modifitseeritud DDD-metoodika. Eesti Arst, 84. 679−679. (9).
5.2.
2005
Metsvaht, T.; Padari, H.; Lutsar, I. (2005). Ampitsilliin-gentamütsiin versus penitsilliin-gentamütsiin varase empiirilise antibakteriaalse ravi valikuna vastsündinutel. Eesti Arst, 84. Eesti Arst, 672−673. (9).
1.1.
2004
Walsh, T.J.; Karlsson, M.O.; Driscoll, T.; Arguedas, A.G.; Adamson, P.; Saez-Llorens, X.; Vora, A.J.; Arrieta, A.C.; Blumer, J.; Lutsar, I.; Milligan, P.; Wood, N. (2004). Pharmacokinetics and safety of intrevenous voriconazole in children after single and multiple dose administration. Antimicrobial Agents and Chemotherapy, 48 (6), 2166−2172.
1.1.
2004
Steinbach, W.J.; Benjamin, D.K.; Kontoyiannis, D.P.; Perfect, J.R.; Lutsar, I.; Marr, K.A.; Lionakis, M.S.; Torres, H.A.; Jafri, H.; Walsh, T.J. (2004). Infections due to Aspergillus terreus: multicenter retrospective analysis of 83 cases. Clinical Infectious Diseases, 39, 192−198.
1.1.
2003
Lutsar, I.; Roffey, S.; Troke, P. (2003). Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clinical Infectious Diseases, 37 (5), 728−732.
1.1.
2003
Lutsar, I.; Hodges, MR.; Tomaszewski, K.; Troke, PF.; Wood, ND. (2003). Safety of voriconazole and dose individualisation. Clinical Infectious Diseases, 36 (8), 1087−1088.
1.1.
2003
Lutsar, I.; Friedland, IR.; Wubbel, L.; Ahmed, A.; Truijllo, M.; McCoig, CC.; Jafri, HH.; McCracken, GH.Jr. (2003). Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis. Journal of Antimicrobial Chemotherapy, 52 (4), 651−655.
1.1.
2003
Perfect, JR.; Marr, KA.; Walsh, TJ.; Greenberg, RN.; Dupont, B.; De La Torre-Cisneros, J.; Just-Nübling, G.; Schlamm, H.; Lutsar, I.; Espinel-Ingroff, A.; Johnson, E. (2003). Voriconazole treatment for less common, emerging or refractory fungal infections. Clinical Infectious Diseases, 36 (9), 1122−1131.
1.3.
2003
Tamm, E.; Kõljalg, S.; Lutsar, I.; Maimets, M.; Naaber, P. (2003). Pneumokokkinfektsioon lapseeas. Eesti Arst, 82 (7), 464−471.
1.1.
2002
Walsh, TJ.; Lutsar, I.; Driscoll, T.; Dupont, B.; Roden, M.; Ghahramani, P.; Hodges, M.; Groll, AH.; Perfect, JR. (2002). Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. The Pediatric Infectious Disease Journal, 21 (3), 240−248.
1.1.
2000
Lutsar, I.; Friedland, IR. (2000). Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clinical Pharmacokinetics, 39 (5), 335−343.
1.1.
2000
Ng, W.; Olsen, K.; Lutsar, I.; Wubbel, L.; Ghaffar, F.; Jafri, H.; McCracken, GH.; Friedland, I. (2000). Buffy coat PCR for diagnosis of experimental pneumococcal pneumonia. Apmis, 108 (11), 729−733.
1.1.
1999
Meriste, S.; Tamm, E.; Willems, P.; Lutsar, I. (1999). Safety and immunogenicity of combined DTPa-IPV for primary and booster vaccination. Scandinavian Journal of Infectious Diseases, 31 (6), 587−591.
1.1.
1999
Ahmed, A.; Jafri, H.; Lutsar, I.; McCoig, CC.; Trujillo, M.; Wubbel, L.; Shelton, S.; McCracken, GH. (1999). Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrobial Agents and Chemotherapy, 43 (4), 876−881.
1.1.
1999
Lutsar, I.; Friedland, IR.; Jafri, HS.; Wubbel, L.; Ng, W.; Ghaffar, F.; McCracken, GH.Jr. (1999). Efficacy of gatifloxacin in experimental Escherichia coli meningitis. Antimicrobial Agents and Chemotherapy, 43 (7), 1805−1807.
1.1.
1999
McCoig, CC.; Friedland, IR.; Lutsar, I.; Jafri, HS.; Wubbel, L.; Olsen, K.; Shelton, S.; McCracken, GH.Jr. (1999). Pharmacodynamics and bactericidal activity of trovafloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis. Journal of Antimicrobial Chemotherapy, 43 (5), 683−688.
1.1.
1999
Ng, W.; Lutsar, I.; Wubbel, L.; Jafri, H.; Ghaffar, F.; McCracken, GH.Jr.; Friedland, IR. (1999). Pharmacodynamics of trovafloxacin in the cephalosporin-resistant pneumococcal pneumonia in immunocompetent mice. Journal of Antimicrobial Chemotherapy, 43 (6), 811−816.
1.1.
1998
Lutsar, I.; Friedland, I.; Wubbel, L.; McCoig, C.; Jafri, H.; Ghaffar, F.; McCracken, G. (1998). Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents and Chemotherapy, 42 (10), 2650−2655.
1.1.
1998
Lutsar, I.; McCracken, GH.; Friedland, IR. (1998). Antibiotic pharmacodynamics in cerebrospinal fluid. Clinical Infectious Diseases, 27 (5), 1117−1127.
1.2.
1998
Friedland, IR.; Lutsar, I. (1998). New Antibiotics. Current Opinion in Pediatrics, 10 (1), 41−45.
1.1.
1997
Lutsar, I.; Ahmed, A.; Friedland, IR.; Trujillo, M.; Wubbel, L.; Olsen, K.; McCracken, GH. (1997). Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrobial Agents and Chemotherapy, 41 (11), 2414−2417.
1.2.
1997
Lutsar, I.; Friedland, IR.; McCracken, GH.Jr. (1997). Pathogenesis of bacterial meningitis. Annales Nestle, 55, 92−102.
1.1.
1996
Siigur, U.; Tamm, E.; Torm, S.; Lutsar, I.; Salminen, S. (1996). Effect of bacterial infection and administration of a probiotic on fecal short-chain fatty acids. Microbial Ecology in Health and Disease, 9 (6), 271−277.
1.1.
1995
Lutsar, I.; Gontmacher, A.; Närska, M.; Rüütel, V.; Topman, M.; Ilves, P.; Siirde, T.; Beilmann, A. (1995). Five days of antibacterial therapy for bacterial meningitis in children. Infection, 23 (2), 113−118.
1.1.
1995
Lutsar, I.; Siirde, T.; Soopold, T. (1995). Long term follow-up of Estonian children after bacterial meningitis. The Pediatric Infectious Disease Journal, 14 (7), 624−625.
1.2.
1995
Sepp, E.; Tamm, E.; Torm, S.; Lutsar, I.; Mikelsaar, M.; Salminen, S. (1995). Impact of a lactobacillus probiotic on the faecal microflora in children with shigellosis. Microecology and Therapy, 23, 74−80.
1.1.
1994
Lutsar, I.; Haldre, S.; Topman, M.; Talvik, T. (1994). Enzymatic changes in the cerebrospinal-fluid in patients with infections of the central-nervous-system. Acta Paediatrica, 83 (11), 1146−1150.
19.03.2021

Irja Lutsar

https://etis.ee/CV/Irja_Lutsar/eng
20.07.1954
737 4171
irja.lutsar@ut.ee
http://

Career

Institutions and positions
11.01.2016–...   
University of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, Head of Office
01.01.2016–...   
University of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, Professor of Medical Microbiology (1,00)
01.01.2016–10.01.2016   
University of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, Head of Office
01.09.2014–31.12.2015   
University of Tartu, Faculty of Medicine, Department of Microbiology, Professor of Medical Microbiology (1,00)
01.09.2014–31.12.2015   
University of Tartu, Faculty of Medicine, Department of Microbiology, Head of Institute
01.09.2012–31.08.2014   
University of Tartu, Faculty of Medicine, Department of Microbiology, Head of Institute
01.09.2009–31.08.2014   
University of Tartu, Faculty of Medicine, Department of Microbiology, Professor of Medical Microbiology and Virology (1,00)
01.09.2009–31.08.2012   
University of Tartu, Faculty of Medicine, Department of Microbiology, Head of Institute
01.11.2007–31.08.2009   
University of Tartu, Faculty of Medicine, Department of Microbiology, Head of Institute
01.11.2004–31.10.2007   
University of Tartu, Faculty of Medicine, Department of Microbiology, Head of Institute
25.10.2004–31.08.2009   
University of Tartu, Faculty of Medicine, Department of Microbiology, Professor of Medical Microbiology and Virology (1,00)
01.01.2003–31.12.2004   
Director, Pfizer Ltd., Global Research and Development, UK
01.01.1999–31.12.2003   
Clinical Project Manager, Pfizer Ltd., Global Research and Development, UK
01.01.1998–31.12.1999   
Associated Professor in Paediatrics, Tartu University, Faculty of Medicine, Paediatric Department
01.01.1995–31.12.1998   
Fellow in paediatric infectious diseases, Southwestern Medical Center at Dallas, USA
01.01.1992–31.12.1995   
Head of Paediatric Infectious Diseases Department, Consultant in paediatric infectious diseases, Tartu University Children’s Hospital, Estonia
01.01.1982–31.12.1992   
Deputy Head of the Paediatric Hospital,Tartu University Children’s Hospital, Estonia
01.01.1979–31.12.1982   
Paediatrician, Võru Hospital, Estonia
01.01.1978–31.12.1979   
Internship in paediatrics, First Children’s Hospital, Tallinn, Estonia
 
 
Education
1995–1998   
Reasearch Fellow in Paediatric Infectious Diseases - Southwestern Medical School, Dallas, Texas, USA
1992–1995   
PhD - University of Tartu
1978–1979   
Internship in Paediatrics, Tallinn First Children's Hospital
1972–1978   
MD - University of Tartu
 
 
R&D related managerial and administrative work
2015−...   
The Paediatric Infectious Disease Journal, sektsiooni toimetaja
2012−...   
Estonian Science Agency, Member of Evaluation Committee
2011−...   
senat member of University of Tartu
2007−...   
EMEA, Pedaitric Committe, member
2010−2013   
European Society for Paediatric Infectious Diseases - board member
2006−2012   
Estonian Science Foundation, Expert Committe of Health Sciences, chair
2005−2010   
EMEA, Scietific Advisory Group on antiinfectives
2002−2005   
European Society for Pediatric Infectious Diseases, Member of scientific committee
1998−1999   
Estonian Infectious Diseases Society, president
1994−1994   
Congress of Estonian Pediatric Association, Tallinn - member of organizing committee
1993−1993   
2nd International Meeting of Baltic Association of Child Neurology, Riga - member of organizing committee
1993−1993   
International symposium Impact of the environment to children’s health, Tartu - secretary general
1992−1994   
Estonian Infectious Diseases Society, Board member
1991−1991   
1st International Meeting of Baltic Association of Child Neurology, Tartu - secretary general
1990−1995   
Estonian Pediatric Association, Board member
1990−1993   
Baltic Association of Child Neurology, Board member
1989−1989   
Congress of Estonian Pediatric Association, Tallinn - member of organizing committee

Qualifications

Academic degrees
Irja Lutsar, Doctor's Degree, 1995, (sup) Tiina Talvik, Kesknärvisüsteemi põletikulised haigused lastel (kliinilis-epidemioloogiline iseloomustus ja kaugtulemused) (Infections of the central nervous system in children (epidemiologic, diagnostic and therapeutic aspects, long term outcome)), University of Tartu, Faculty of Medicine.
 
 
Honours & awards
2014, Irja Lutsar, Tartu Ülikooli suur medal
2013, Irja Lutsar, Eesti Vabariigi Punase Risti II klassi orden
2010, Irja Lutsar, Estonian Covernment Annual Award in Medical Sciences
2010, Irja Lutsar, Infektsioonide käsitlus omandatud immuunpuudulikkusega isikutel
1995, Irja Lutsar, European Society for Pediatric Infectious Diseases fellowship award
1994, Irja Lutsar, Estonian Government award in medical science, 1994European Society for Pediatric Infectious Diseases fellowship award, 1995
 
 
Fields of research
ETIS CLASSIFICATION: 3. Health; 3.7. Clinical Medicine; CERCS CLASSIFICATION: B510 Infections
ETIS CLASSIFICATION: 3. Health; 3.11. Biochemistry, Genetics, Microbiology, Biotechnology, Molecular Biology, Cell Biology, Biophysics and Bioinformatics relating to Health Studies
ETIS CLASSIFICATION: 3. Health; 3.7. Clinical Medicine; SPECIFICATION: Infections in neonates, their pathogenesis and management. Infections of the central nervous system in children, their pathogenesis, treatment and long term outcome . Pharmacokinetic and pharmacodynamic properties of antiinfective agents in children . HIV infection, the importance of recombinant viruses in the disease process.
 
 
Additional information
Ei ole lisainfot

Projects in progress

Completed projects

Dissertations under supervision

Supervised dissertations

Publications

Category
Year
Publication
 
2.4.
2022
Merits, Andres; Abroi, Aare; Kurg, Reet; Žusinaite, Eva; Truve, Erkki; Sarmiento, Cecilia; Sõmera, Merike; Saar, Tiiu; Viltrop, Arvo; Lutsar, Irja; Avi, Radko; Karki, Tõnis; Huik, Kristi; Kõljalg, Siiri; Brilene, Tatjana; Roots, Irja;Inno, Heleri (2022). Üldine ja Meditsiiniline viroloogia. Tartu: Tartu Ülikooli kirjastus [forthcoming].
1.1.
2020
Jõgi, Piia; Soeorg, Hiie; Oona, Marje; Kaart, Tanel; Toompere, Karolin; Maskina, Tereza; Koort, Iris; Rätsep, Anneli; Lutsar, Irja; , (2020). Dynamics of pertussis toxin IgG after symptomatic pertussis in children and adults. Vaccine, 38 (16), 3196−3200. DOI: 10.1016/j.vaccine.2020.02.080.
1.1.
2020
Lutsar, Irja; Chazallon, Corine; Trafojer, Ursula; de Cabre, Vincent Meiffredy; Auriti, Cinzia; Bertaina, Chiara; Calo Carducci, Francesca Ippolita; Canpolat, Fuat Emre; Esposito, Susanna; Fournier, Isabelle; Hallik, Maarja; Heath, Paul T; Ilmoja, Mari-Liis; Iosifidis, Elias; Kuznetsova, Jelena; Meyer, Laurence; Metsvaht, Tuuli; Mitsiakos, George; Pana, Zoi Dorothea; Mosca, Fabio ... , (2020). Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial. PLoS ONE, 15 (3), e0229380−e0229380. DOI: 10.1371/journal.pone.0229380.
1.1.
2020
Kõivumägi, Kadri; Toompere, Karolin; Soeorg, Hiie; Kallas, Eveli; Jõgeda, Ene-Ly; Huik, Kristi; Lutsar, Irja (2020). Acute gastroenteritis hospitalizations after implementation of universal mass vaccination against rotavirus. Vaccine, 38 (13), 2879−2886. DOI: 10.1016/j.vaccine.2020.01.098.
1.1.
2020
Andersen, Petter I.; Ianevski, Aleksandr; Lysvand, Hilde; Vitkauskiene, Astra; Oksenych, Valentyn; Bjørås, Magnar; Telling, Kaidi; Lutsar, Irja; Dampis, Uga; Irie, Yasuhiko; Tenson, Tanel; Kantele, Anu; Kainov, Denis E. (2020).

Discovery and development of safe-in-man broad-spectrum antiviral agents

. International Journal of Infectious Diseases, 93, 268−276. DOI: 10.1016/j.ijid.2020.02.018.
1.1.
2020
Telling, Kaidi; Brauer, Age; Laht, Mailis; Kalmus, Piret; Toompere, Karolin; Kisand, Veljo; Maimets, Matti; Remm, Maido; Tenson, Tanel; Lutsar, Irja (2020). Characteristics of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae and Contact to Animals in Estonia. Microorganisms, 8 (8). DOI: 10.3390/microorganisms8081130.
5.2.
2020
Tiit-Vesingi, Annika; Soeorg, Hiie; Truusalu, Kai; Hoidmets, Dagmar; Rööp, Tiiu; Laas, Hanna-Kadri; Lutsar, Irja; Metsvaht, Tuuli (2020). Staphylococcus epidermidis’e suur genotüübiline mitmekesisus perekeskses vastsündinute intensiivravi osakonnas. Eesti Arst, 99 (Lisa 2): Tartu Ülikooli arstiteaduskonna aastapäeva teaduskonverents 2020; Tartu, Eesti; 15.-16. oktoober 2020. OÜ Celsius Healthcare, 24.
1.1.
2019
Soeorg, Hiie; Metsvaht, Hanna Kadri; Keränen, Evamaria Elisabet; Eelmäe, Imbi; Merila, Mirjam; Ilmoja, Mari-Liis; Metsvaht, Tuuli; Lutsar, Irja. (2019). Genetic Relatedness of Staphylococcus haemolyticus in Gut and Skin of Preterm Neonates and Breast Milk of Their Mothers. The Pediatric Infectious Disease Journal.10.1097/INF.0000000000002056.
1.1.
2019
Huik, Kristi; Soodla, Pilleriin; Pauskar, Merit; Owen, S. Michele; Luo, Wei; Murphy, Gary; Jogeda, Ene-Ly; Kallas, Eveli; Rajasaar, Heli; Avi, Radko; Masciotra, Silvina; Lutsar, Irja; Del Amo, Julia; Meyer, Laurence; Bucher, Heiner C.; Chene, Genevieve; Hamouda, Osamah; Pillay, Deenan; Prins, Maria; Rosinska, Magda ... Scott, Martin (2019). The concordance of the limiting antigen and the Bio-Rad avidity assays in persons from Estonia infected mainly with HIV-1 CRF06_cpx. PLoS ONE, 14 (5), ARTN e0217048. DOI: 10.1371/journal.pone.0217048.
1.1.
2019
Mesek, Inge; Nellis, Georgi; Lass, Jana; Metsvaht, Tuuli; Varendi, Heili; Visk, Helle; Turner, Mark A; Nunn, Anthony J; Duncan, Jennifer; Lutsar, Irja (2019). Medicines prescription patterns in European neonatal units. International Journal of Clinical Pharmacy. DOI: 10.1007/s11096-019-00923-2.
1.1.
2019
Esposito, Susanna; Stefanelli, Paola; Fry, Norman K; Fedele, Giorgio; He, Qiushui; Paterson, Pauline; Tan, Tina; Knuf, Markus; Rodrigo, Carlos; Weil Olivier, Catherine; Flanagan, Katie L; Hung, Ivan; Lutsar, Iria; Edwards, Kathryn; O'Ryan, Miguel; Principi, Nicola; , (2019). Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines. Frontiers in Immunology, 10, 1344−1344.10.3389/fimmu.2019.01344.
1.1.
2019
Jacqz-Aigrain, Evelyne; Leroux, Stéphanie; Thomson, Alison H; Allegaert, Karel; Capparelli, Edmund V; Biran, Valérie; Simon, Nicolas; Meibohm, Bernd; Lo, Yoke-Lin; Marques, Remedios; Peris, José-Esteban; Lutsar, Irja; Saito, Jumpei; Nakamura, Hidefumi; van den Anker, Johannes N; Sharland, Mike; Zhao, Wei (2019). Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. Journal of Antimicrobial Chemotherapy, 74 (8), 2128−2138. DOI: 10.1093/jac/dkz158.
1.1.
2019
Ianevski, Aleksandr; Zusinaite, Eva; Shtaida, Nastassia; Kallio-Kokko, Hannimari; Valkonen, Miia; Kantele, Anu; Telling, Kaidi; Lutsar, Irja; Letjuka, Pille; Metelitsa, Natalja; Oksenych, Valentyn; Dumpis, Uga; Vitkauskiene, Astra; Stašaitis, Kestutis; Öhrmalm, Christina; Bondeson, Kåre; Bergqvist, Anders; Cox, Rebecca J; Tenson, Tanel; Merits, Andres ... Kainov, Denis E (2019). Low Temperature and Low UV Indexes Correlated with Peaks of Influenza Virus Activity in Northern Europe during 2010⁻2018. Viruses, 11 (3), 11(3). DOI: 10.3390/v11030207.
1.1.
2019
Folgori, Laura; Lutsar, Irja; Standing, Joseph F; Walker, A Sarah; Roilides, Emmanuel; Zaoutis, Theoklis E; Jafri, Hasan; Giaquinto, Carlo; Turner, Mark A; Sharland, Mike (2019). Standardising neonatal and paediatric antibiotic clinical trial design and conduct: the PENTA-ID network view. BMJ Open, 9 (12), e032592−e032592. DOI: 10.1136/bmjopen-2019-032592.
5.2.
2019
Tiit, Annika; Soeorg, Hiie; Tammaru, Marika; Eelmäe, Imbi; Ilmoja, Mari-Liis; Metsvaht, Tuuli; Lutsar, Irja (2019). Rinnapiima kolonisatsioon mecA-positiivsete koagulaasnegatiivsete stafülokokkidega kolmes vastsündinute intensiivravi osakonnas. Eesti Arst. Eesti Lastearstide Seltsi XXII kongressi teesid, 98 (Lisa 2): Eesti Lastearstide Seltsi XXII Kongress; Tartu, Eesti; 30.05.-01.06.2019. Publicon, 60.
5.2.
2019
Jõgi, P.; Soeorg, H.; Oona, M.; Kaart, T.; Maskina, T.; Koort, I.; Rätsep. A.; Lutsar. I. (2019). Läkaköha toksiini vastaste antikehade püsimine lastel ja täiskasvanutel pärast läkaköha põdemist. Eesti Arst (23−23). Eesti Latearstide Seltsi XXII kongress.
1.1.
2018
P Soodla, R Simmons, K Huik, M Pauskar, E-L Jõgeda, H Rajasaar, E Kallaste, M Maimets, R Avi, G Murphy, K Porter, I Lutsar and for the Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE) Collaboration in EuroCoord (2018). HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay. HIV Medicine, 19 (1), 33−41.10.1111/hiv.12535.
1.1.
2018
Pansa, Paola; Hsia, Yingfen; Bielicki, Julia; Lutsar, Irja; Walker, A Sarah; Sharland, Mike; Folgori, Laura (2018). Evaluating Safety Reporting in Paediatric Antibiotic Trials, 2000-2016: A Systematic Review and Meta-Analysis. Drugs. DOI: 10.1007/s40265-017-0850-x.
1.1.
2018
Padari, Helgi; Metsvaht, Tuuli; Germovsek, Eva; Barker, Charlotte; Kipper, Karin; Herodes, Koit; Standing, Joseph; Oselin, Kersti; Tasa, Tõnis; Soeorg, Hiie; Lutsar, Irja (2018). Pharmacokinetics of penicillin G in preterm and term neonates. Antimicrobial Agents and Chemotherapy.10.1128/AAC.02238-17.
1.1.
2018
Kogermann, Karin; Lass, Jana; Nellis, Georgi; Metsvaht, Tuuli; Lutsar, Irja (2018). Age-appropriate formulations including pharmaceutical excipients in neonatal medicines. Current Pharmaceutical Design, 23, 5779−5789. DOI: 10.2174/1381612823666170926122613.
1.1.
2018
Germovsek, Eva; Lutsar, Irja; Kipper, Karin; Karlsson, Mats O.; Planche, Tim; Chazallon, Corine; Meyer, Laurence; Trafojer, Ursula M. T.; Metsvaht, Tuuli; Fournier, Isabelle; Sharland, Mike; Heath, Paul; Standing, Joseph F.; on behalf of the NeoMero Consortium (2018). Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies. Journal of Antimicrobial Chemotherapy, 73 (Article), 1908−1916.10.1093/jac/dky128.
1.1.
2018
Jõgi, Piia; Oona, Marje; Kaart, Tanel; Toompere, Karolin; Maskina, Tereza; Koort, Iris; Rätsep, Anneli; Lutsar, Irja (2018). Pertussis and parapertussis in children and adults with a persistent cough: an observational study. Infection, 46 (1), 83−91. DOI: 10.1007/s15010-017-1095-z.
1.1.
2018
Ianevski, Aleksandr; Zusinaite, Eva; Kuivanen, Suvi; Strand, Marten; Lysvand, Hilde; Teppor, Mona; Kakkola, Laura; Paavilainen, Henrik; Laajala, Mira; Kallio-Kokko, Hannimari; Valkonen, Miia; Kantele, Anu; Telling, Kaidi; Lutsar, Irja; Letjuka, Pille; Metelitsa, Natalja; Oksenych, Valentyn; Bjoras, Magnar; Nordbo, Svein Arne; Dumpis, Uga ... Kainov, Denis (2018). Novel activities of safe-in-human broad-spectrum antiviral agents. Antiviral Research, 154, 174−182. DOI: 10.1016/j.antiviral.2018.04.016.
1.1.
2018
Soeorg, Hiie; Treumuth, Sirli; Metsvaht, Hanna Kadri; Eelmäe, Imbi; Merila, Mirjam; Ilmoja, Mari-Liis; Lutsar, Irja; Metsvaht, Tuuli. (2018). Higher intake of coagulase-negative staphylococci from maternal milk promotes gut colonization with mecA-negative Staphylococcus epidermidis in preterm neonates. Journal of Perinatology.10.1038/s41372-018-0183-y.
1.1.
2018
Jõgeda, E-L; Avi, R; Pauskar, M; Kallas, E; Karki, T; Des Jarlais, D; Uusküla, A; Toompere, K; Lutsar, I; Huik, K (2018). Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs. Journal of Medical Virology, 90 (11), 1779−1783. DOI: 10.1002/jmv.25258.
1.1.
2018
Dyar, OJ; Nathwani, D; Monnet, DL; Gyssens, IC; Stålsby Lundborg, C; Pulcini, C; ESGAP Student-PREPARE Working Group (2018). Do medical students feel prepared to prescribe antibiotics responsibly? Results from a cross-sectional survey in 29 European countries. Journal of Antimicrobial Chemotherapy, 73 (8), 2236.10.1093/jac/dky150.
1.1.
2018
Parm, Ülle; Štšepetova, Jelena; Eelmäe, Imbi; Merila, Mirjam; Ilmoja, Mari-Liis; Metsvaht, Tuuli; Lutsar, Irja; Soeorg, Hiie (2018). Genetic relatedness of Gram-negative bacteria colonizing gut and skin of neonates and mother's own milk. Journal of Perinatology, 38, 1503−1511. DOI: 10.1038/s41372-018-0220-x.
1.1.
2018
Telling, Kaidi; Laht, Mailis; Brauer, Age; Remm, Maido; Kisand, Veljo; Maimets, Matti; Tenson, Tanel; Lutsar, Irja (2018). Multidrug resistant Pseudomonas aeruginosa in Estonian hospitals. BMC Infectious Diseases, 18 (1), ARTN 513. DOI: 10.1186/s12879-018-3421-1.
5.2.
2018
Lemsalu L, Rice B, Uusküla A, Raag M, Lutsar I, Rüütel K (2018). How to ascertain an accurate number of people living with diagnosed HIV and fill data gaps from the past - lessons learned from a high prevalence setting in Europe. 22nd International AIDS Conference, Amsterdam, the Netherlands, 23-27 July 2018. International AIDS Society.
1.1.
2017
Veigure, Ruta; Aro, Rudolf; Metsvaht, Tuuli; Standing, Joseph F.; Lutsar, Irja; Herodes, Koit; Kipper, Karin (2017). A Highly Sensitive Method for the Simultaneous UHPLC-MS/MS Analysis of Clonidine, Morphine, Midazolam and their Metabolites in Blood Plasma Using HFIP as the Eluent Additive. Journal of Chromatography B, 1052, 150−157. DOI: 10.1016/j.jchromb.2017.03.007.
1.1.
2017
Soeorg H, Huik K, Parm Ü, Ilmoja ML, Metsvaht T, Lutsar I (2017). Molecular epidemiology of Staphylococcus epidermidis in neonatal intensive care units. APMIS, 125, 63−73. DOI: 10.1111/apm.12637.
1.1.
2017
Soeorg, Hiie; Metsvaht, Tuuli; Eelmäe, Imbi; Metsvaht, Hanna Kadri; Treumuth, Sirli; Merila, Mirjam; Ilmoja, Mari-Liis; Lutsar, Irja (2017). Coagulase-Negative Staphylococci in Human Milk From Mothers of Preterm Compared With Term Neonates. Journal of Human Lactation, 33 (2), 329−340. DOI: 10.1177/0890334417691505.
1.1.
2017
Tasa, Tõnis; Metsvaht, Tuuli; Kalamees, Riste; Vilo, Jaak; Lutsar, Irja (2017). DosOpt: A Tool for Personalized Bayesian Dose Adjustment of Vancomycin in Neonates. Therapeutic Drug Monitoring, 39 (6), 604−613. DOI: 10.1097/FTD.0000000000000456.
1.1.
2017
Jogeda, Ene-Ly; Huik, Kristi; Pauskar, Merit; Kallas, Eveli; Karki, Tonis; Jarlais, Don Des; Uuskula, Anneli; Lutsar, Irja; Avi, Radko (2017). Prevalence and Genotypes of GBV-C and Its Associations With HIV Infection Among Persons Who Inject Drugs in Eastern Europe. Journal of Medical Virology, 89 (4), 632−638.10.1002/jmv.24683.
1.1.
2017
Soeorg, Hiie; Metsvaht, Tuuli; Eelmäe, Imbi; Merila, Mirjam; Treumuth, Sirli; Huik, Kristi; Jürna-Ellam, Marika; Ilmoja, Mari-Liis; Lutsar, Irja (2017). The role of breast milk in the colonization of neonatal gut and skin with coagulase-negative staphylococci. Pediatric Research, 82 (5), 759−767.10.1038/pr.2017.150.
1.1.
2017
Thompson, Georgina; Barker, Charlotte I; Folgori, Laura; Bielicki, Julia A; Bradley, John S; Lutsar, Irja; Sharland, Mike (2017). Global shortage of neonatal and paediatric antibiotic trials: rapid review. BMJ Open, 7 (10), e016293−e016293.10.1136/bmjopen-2017-016293.
1.1.
2017
Taba, P; Schmutzhard, E; Forsberg, P; Lutsar, I; Ljøstad, U; Mygland, Å; Levchenko, I; Strle, F; Steiner, I (2017). EAN consensus review on prevention, diagnosis and management of tick-borne encephalitis. European Journal of Neurology, 24 (10), 1214−1e61.10.1111/ene.13356.
5.2.
2017
Jõgi, P.; Oona, M.; Kaart, T.; Toompere, K.; Maskina, T.; Koort, I.; Rätsep, A.; Lutsar, I. (2017). Läkaköha toksiini vastaste IgG-tüüpi antikehade tase läkaköhaga patsientide hulgas ning kolme aasta jooksul pärast haiguse põdemist. 96. Eesti Arst, 16. (Lisa 1).
5.2.
2017
Parm, Ü.; Soeorg, H.; Štšepetova, J.; Metsvaht, T.; Ilmoja, ML.; Lutsar, I. (2017). Gram-negative opportunistic microorganisms colonising the skin and gut of neonates and breast milk of their mothers. European Congress on Clinical Microbiology and Infectious Diseases; 22-25.04.2017. Vienna, Austria.. ECCMID.
5.2.
2017
Metsvaht, Hanna Kadri; Metsvaht, Tuuli; Eelmäe, Imbi; Merila, Mirjam; Lutsar, Irja; Ilmoja, Mari-Liis; Soeorg, Hiie (2017). Skin and gut colonisation with Staphylococcus haemolyticus in term and preterm neonates. European Society for Paediatric Infectious Diseases,.
1.1.
2016
Huik, Kristi; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Jõgeda, Ene-Ly; Karki, Tõnis; Rüütel, Kristi; Talu, Ave; Abel-Ollo, Katri; Uusküla, Anneli; Carrillo, Andrew; Ahuja, Sunil K; He, Weijing; Lutsar, Irja (2016). A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs. PLoS ONE, 11 (6), e0156850−e0156850. DOI: 10.1371/journal.pone.0156850.
1.1.
2016
Germovsek, Eva; Kent, Alison; Metsvaht, Tuuli; Lutsar, Irja; Klein, Nigel; Turner, Mark A; Sharland, Mike; Nielsen, Elisabet I; Heath, Paul T; Standing, Joseph F (2016). Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants. Antimicrobial Agents and Chemotherapy, 60 (8), 4869−4877. DOI: 10.1128/AAC.00577-16.
1.1.
2016
Folgori, Laura; Bielicki, Julia; Ruiz, Beatriz; Turner, Mark A; Bradley, John S; Benjamin, Daniel K; Zaoutis, Theoklis E; Lutsar, Irja; Giaquinto, Carlo; Rossi, Paolo; Sharland, Mike (2016). Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review. The Lancet: Infectious Diseases, 16 (9), 178−189.10.1016/S1473-3099(16)00069-4.
1.1.
2016
Nellis, Georgi; Metsvaht, Tuuli; Varendi, Heili; Lass, Jana; Duncan, Jennifer; Nunn, Anthony J; Turner, Mark A; Lutsar, Irja (2016). Product Substitution as a Way Forward in Avoiding Potentially Harmful Excipients in Neonates. Pediatric Drugs, 18 (3), 221−230. DOI: 10.1007/s40272-016-0173-5.
1.1.
2016
Pantazis, Nikos; Touloumi, Giota; Meyer, Laurence; Olson, Ashley; Costagliola, Dominique; Kelleher, Anthony D; Lutsar, Irja; Chaix, Marie-Laure; Fisher, Martin; Moreno, Santiago; Porter, Kholoud; , (2016). The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. AIDS (London, England), 30 (6), 879−888. DOI: 10.1097/QAD.0000000000000991.
1.1.
2016
Brauer, Age; Telling, Kaidi; Laht, Mailis; Kalmus, Piret; Lutsar, Irja; Remm, Maido; Kisand, Veljo; Tenson, Tanel (2016). Plasmid with colistin resistance gene mcr-1 in ESBL-producing Escherichia coli strains isolated from pig slurry in Estonia. Antimicrobial Agents and Chemotherapy, 60 (11), 6933−36. DOI: 10.1128/AAC.00443-16.
1.1.
2016
Avi, Radko; Pauskar, Merit; Karki, Tõnis; Kallas, Eveli; Jõgeda, Ene-Ly; Margus, Tõnu; Huik, Kristi; Lutsar, Irja (2016). Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia. Journal of Medical Virology, 88 (3), 448−454. DOI: 10.1002/jmv.24361.
1.1.
2016
Kallas, Eveli; Huik, Kristi; Türk, Silver; Pauskar, Merit; Jõgeda, Ene-Ly; Šunina, Marina; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja (2016). T Cell Distribution in Relation to HIV/HBV/HCV Coinfections and Intravenous Drug Use. Viral Immunology, 0−0. DOI: 10.1089/vim.2016.0057.
1.1.
2016
Kallas, Eveli; Huik, Kristi; Türk, Silver; Pauskar, Merit; Jõgeda, Ene-Ly; Šunina, Marina; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja (2016). Differences in T cell distribution and CCR5 expression in HIV-positive and HIV-exposed seronegative persons who inject drugs. Medical microbiology and immunology, 205 (3), 231−239. DOI: 10.1007/s00430-015-0444-8.
1.1.
2016
Jõgeda, Ene-Ly; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Lutsar, Irja; Huik, Kristi (2016). Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe. Infection Genetics and Evolution, 43, 83−85.10.1016/j.meegid.2016.05.022.
1.1.
2016
Padari, Helgi; Oselin, Kersti; Tasa, Tõnis; Metsvaht, Tuuli; Lõivukene, Krista; Lutsar, Irja (2016). Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target? BMC Pediatrics, 16 (1), 206−206. DOI: 10.1186/s12887-016-0753-0.
1.1.
2016
Laisaar, K.T.; Raag, M.; Lutsar, I.; Uusküla, A. (2016). People living with HIV in Estonia: engagement in HIV care in 2013. Eurosurveillance, 21 (43), x−x. DOI: 10.2807/1560-7917.ES.2016.21.43.30380.
5.2.
2016
Soeorg, H.; Metsvaht, T.; Eelmäe, I.; Treumuth, S.; Merila, M.; Ilmoja, ML.; Lutsar, I. (2016). High prevalence of mecA-positive coagulase-negative staphylococci (MR-CoNS) in breast milk (BM) of mothers of preterm neonates. The 34th Annual Meeting of the ESPID, May 10-14, 2016, Brighton, UK. European Society for Paediatric Infectious Diseases,.
5.2.
2016
Mesek, Inge; Nellis, Georgi; Metsvaht, Tuuli; Visk, Helle; Lass, Jana; Lutsar, Irja (2016). The impact of gestational age and geographical region on anti-infectives’ use in European neonatal intensive care units (NICU). In: . 34th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), 10.-14.05.2016, Brighton, UK.
1.1.
2015
Jõgi, P.; Oona, M.; Toompere, K.; Lutsar, I. (2015). Estimated and reported incidence of pertussis in Estonian adults: A seroepidemiological study. Vaccine, 33 (38), 4756−4761. DOI: 10.1016/j.vaccine.2015.08.007.
1.1.
2015
Soodla, P.; Rajasaar, H.; Avi, R.; Zilmer, K.; Kink, K.; Novikova, L.; Huik, K.; Maimets, M.; Lutsar, I. (2015). Design and structure of the Estonian HIV Cohort Study (E-HIV). Infectious Diseases, 47 (11), 768−675. DOI: 10.3109/23744235.2015.1061203.
1.1.
2015
Parm, Ülle; Metsvaht, Tuuli; Ilmoja, Mari-Liis; Lutsar, Irja (2015). Gut colonization by aerobic microorganisms is associated with route and type of nutrition in premature neonates. Nutrition Research, 35 (6), 496−503.10.1016/j.nutres.2015.04.006.
1.1.
2015
Metsvaht, Tuuli; Nellis, Georgi; Varendi, Heili; Nunn, Anthony; Graham, Susan; Rieutord, Andre; Storme, Thomas; McElnay, James; Mulla, Hussain; Turner, Mark; Lutsar, Irja (2015). High variability in the dosing of commonly used antibiotics revealed by a Europewide point prevalence study: implications for research and dissemination. BMC Pediatrics, 15 (41), 1−10. DOI: 10.1186/s12887-015-0359-y.
1.1.
2015
Kallas, E.; Huik, K.; Pauskar, M.; Jõgeda, E.-L.; Karki, T.; Des Jarlais, D.; Uusküla, A.; Avi, R.; Lutsar, I. (2015). Influence of interleukin 10 polymorphisms -592 and -1082 to the HIV, HBV and HCV serostatus among intravenous drug users. Infection Genetics and Evolution, 30, 175−180.10.1016/j.meegid.2014.12.023.
1.1.
2015
Mulla, Hussain; Yakkundi, Shirish; McElnay, James; Lutsar, Irja; Metsvaht, Tuuli; Varendi, Heili; Nellis, Georgi; Nunn, Anthony; Duncan, Jennifer; Pandya, Hitesh; Turner, Mark (2015). An observational study of blood concentrations and kinetics of methyl- and propyl-parabens in neonates. Pharmaceutical Research, 32 (3), 1084−1093. DOI: 10.1007/s11095-014-1520-2.
1.1.
2015
Koljalg, Siiri; Telling, Kaidi; Huik, Kristi; Murruste, Marko; Saarevet, Virve; Pauskar, Merit; Lutsar, Irja (2015). First report of Wohlfahrtiimonas chitiniclastica from soft tissue and bone infection at an unusually high northern latitude. Folia Microbiologica, 60 (2), 155−158.10.1007/s12223-014-0355-x.
1.1.
2015
Rhee, S.-Y.; Blanco, J.L.; Jordan, M.R.; Taylor, J.; Lemey, P.; Varghese, V.; Hamers, R.L.; Bertagnolio, S.; de Wit, T.F.R.; Aghokeng, A.F.; Albert, J.; Avi, R.; Avila-Rios, S.; Bessong, P.O.; Brooks, J.I.; Boucher, C.A.B.; Brumme, Z.L.; Busch, M.P.; Bussmann, H.; Chaix, M.-L. ... Shafer, R.W. (2015). Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLoS Medicine, 12 (4), e1001810.10.1371/journal.pmed.1001810.
1.1.
2015
Nellis, Georgi; Metsvaht, Tuuli; Varendi, Heili; Toompere, Karolin; Lass, Jana; Mesek, Inge; Nunn, Anthony; Turner, Mark; Lutsar, Irja (2015). Potentially harmful excipients in neonatal medicines: a pan-European observational study. Archives of Disease in Childhood, 100 (7), 694−699. DOI: 10.1136/archdischild-2014-307793.
1.3.
2015
Parm, Ü.; Niitvägi, E.; Beljaev, K.; Aro, T.; Aotäht, E.; Raska, K.; Epštein, J.; Oona, M.; Lutsar, I. (2015). Puukborrelioos Saaremaal. Eesti Arst, 94 (4), 203−210.
3.1.
2015
Taba, P.; Lutsar, I. (2015). Chronic infectious inflammatory diseases of the central nervous system. In: Deisenhammer, F.; Sellebjerg, F.; Teunissen, C.E.; Tumani, H. (Ed.). Cerebrospinal Fluid in Clinical Neurology (211−245).. Springer.10.1007/978-3-319-01225-4_15.
5.2.
2015
Soeorg H, Huik K, Parm Ü, Ilmoja ML, Metsvaht T, Lutsar I. (2015). Molecular epidemiology of Staphylococcus epidermidis colonizing gastrointestinal tract of neonates hospitalized to intensive care unit. The 25th European Congress of Clinical Microbiology and Infectious Diseases, April 25-28, 2015, Copenhagen, Denmark..
5.2.
2015
Soeorg H, Metsvaht T, Eelmäe I, Merila M, Ilmoja ML, Lutsar I. (2015). Colonization of gastrointestinal tract (GIT) of preterm neonates with Staphylococcus epidermidis (SE) present in mother’s own unpasteurized breast milk (BM). The 33rd Annual Meeting of the European Society for Paediatric Infectious Diseases, May 12-16, 2015, Leipzig, Germany..
5.2.
2015
Nellis, Georgi; Varendi, Heili; Lutsar, Irja; Metsvaht, Tuuli (2015). Kõik Euroopa vastsündinutele manustatavad teadaolevate kõrvaltoimetega abiained ei ole hädavajalikud. Eesti Arst: TÜ Arstiteaduskonna aastapäeva teaduskonverents, Tartu, Eesti, 2015. , 12.
5.2.
2015
Nellis, Georgi; Lutsar, Irja; Varendi, Heili; Turner, Mark; Metsvaht, Tuuli (2015). Potentially harmful excipients in medicines prescribed in neonatal intensive care units (NICUs) – product substitution as a way forward. J Pediatr Neonat Individual Med: 1st Congress of joint European Neonatal Societies (jENS), Budapest, Hungary, 2015.
5.2.
2015
Rööp, Tiiu; Parm, Ülle; Metsvaht, Tuuli; Ilmoja, Mari-Liis; Lutsar, Irja; Mändar, Reet. (2015). Collection of antibiotic resistant microbes of neonatal origin in the Human Microbiota Biobank (HUMB) at the Department of Microbiology, University of Tartu. XXXIV ECCO meeting: European Culture Collections as tools in research and biotechnology, Institut Pasteur (CRBIP) in Paris, France, 27-29 May, 2015.
5.2.
2015
Jõgi, P.; Oona, M.; Lutsar, I. (2015). Pertussis epidemiology and clinical characteristics in Estonia. 3rd Baltic Paediatric Congress, Riga, Lativa, 19-21 August, 2015.
5.2.
2015
Jõgi, P.; Oona, M.; Toompere, K.; Lutsar, I. (2015). Estimated versus reported incidence of pertussis in Estonian adults. 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 25-28, 2015.
5.2.
2015
Jõgi, P.; Oona, M.; Epstein, J.; Lutsar, I. (2015). Epidemiology of pertussis in Estonian infants over the last 25 years. 33rd Annual Meeting of the European Society for Paediatric Infectious Diseases. Leipzig, Germany , May 12-16, 2015.
5.2.
2015
Kogermann, Karin; Putrinš, Marta; Lippus, Markus; Smidt, Imbi; Truusalu, Kai; Lutsar, Irja; Tenson, Tanel (2015). Bacterial phenotypic heterogeneity – single-cell level methods to study antimicrobial susceptibility during infection. In: . 6th BBBB Conference on Pharmaceutical Sciences, 10.-12.09.2015, Helsinki, Finland.
5.2.
2015
Kogermann, Karin; Putrins, Marta; Lippus, Markus; Smidt, Imbi; Truusalu, Kai; Lutsar, Irja; Tenson, Tanel (2015). Development of Escherichia coli systemic infection model for monitoring persisters and antibiotic susceptibility. In: . ECCMID 2015 Copenhagen, Denmark, 25-28 April 2015. ECCMID 2015 Copenhagen, Denmark, 25-28 April 2015.
5.2.
2015
Jõgeda, Ene-Ly; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Karki, Tõnis; Jarlais, Don Des; Uusküla, Anneli; Lutsar, Irja; Huik, Kristi; (2015). HTLV-1/2 is rare among Eastern-European intravenous drug users (IDUs). Retrovirology, 12, P79−P79. DOI: doi.org/10.1186/1742-4690-12-S1-P79.
5.2.
2015
Mesek, Inge; Nellis, Georgi; Metsvaht, Tuuli; Visk, Helle; Lass, Jana; Lutsar, Irja (2015). Regionaalsed erinevused Euroopas hospitaliseeritud vastsündinute ravimikasutuses. Tartu Ülikooli arstiteaduskonna aastapäeva teaduskonverents, Tartu, 8.-9. oktoober 2015.
5.2.
2015
Mesek, Inge; Nellis, Georgi; Lass, Jana; Lutsar, Irja (2015). Medication use in Neonatal Intensive Care Units across Europe. In: . European Society for Developmental Perinatal and Pediatric Pharmacology (ESDPPP), Belgrade, Serbia, 23.-26. June, 2015.
5.2.
2015
Mesek, Inge; Nellis, Georgi; Lass, Jana; Lutsar, Irja (2015). Medicines use at the European Neonatal Departments. In: . Nordic Social Pharmacy and Health Services Research Conference & Nordic Networking Group for Clinical Pharmacy Conference (NSPC&NNGCP), Tartu, 3.-5. June 2015.
6.8.
2015
Standing, Joseph F; Anderson, Brian J; Holford, Nicholas H G; Lutsar, Irja; Metsvaht, Tuuli (2015). Comment on Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design. Clinical Pharmacokinetics, 54 (12), 1287−1288. DOI: 10.1007/s40262-015-0344-5.
1.1.
2014
Huik, K.; Avi, R.; Uibopuu, H.; Pauskar, M.; Margus, T.; Karki, T.; Krispin, T.; Kool, P.; Rüütel, K.; Talu, A.; Abel-Ollo, K.; Uusküla, A.; Carrillo, AQ.; He, W.; Ahuja, SK.; Lutsar, I. (2014). Association between HIV-1 tropism and CCR5 human haplotype E in a Caucasian population. Jaids-Journal of Acquired Immune Deficiency Syndromes, 66 (3), 239−244. DOI: 10.1097/QAI.0000000000000127.
1.1.
2014
Lutsar, I.; Chazallon, C.; Carducci, FI.; Trafojer, U.; Abdelkader, B.; de Cabre, VM.; Esposito, S.; Giaquinto, C.; Heath, PT.; Ilmoja, ML.; Katragkou, A.; Lascoux, C.; Metsvaht, T.; Mitsiakos, G.; Netzer, E.; Pugni, L.; Roilides, E.; Saidi, Y.; Sarafidis, K.; Sharland, M. ... Aboulker, JP. (2014). Current management of late onset neonatal bacterial sepsis in five European countries. European Journal of Pediatrics, 173 (8), 997−1004.10.1007/s00431-014-2279-5.
1.1.
2014
Mitt, P.; Metsvaht, T.; Adamson, V.; Telling, K..; Naaber, P.; Lutsar, I.; Maimets , M. (2014). Five-year prospective surveillance of nosocomial bloodstream infections in an Estonian paediatric intensive care unit. Journal of Hospital Infection, 86 (2), 95−99. DOI: 10.1016/j.jhin.2013.11.002.
1.1.
2014
Turner, MA.; Duncan, JC.; Shah, U.; Metsvaht, T.; Varendi, H.; Nellis, G.; Lutsar, I.; Yakkundi, S.; McElnay, JC.; Pandya, H.; Mulla, H.; Vaconsin, P.; Storme, T.; Rieutord, A.; Nunn, AJ. (2014). Risk assessment of neonatal excipient exposure: Lessons from food safety and other areas. Advanced Drug Delivery Reviews, 73, 89−101. DOI: 10.1016/j.addr.2013.11.003.
1.1.
2014
Avi, R; Huik, K; Pauskar, M; Ustina, V; Karki, T; Kallas, E; Jõgeda, EL; Krispin, T; Lutsar, I (2014). Transmitted drug resistance is still low in newly diagnosed human immunodeficiency virus type 1 CRF06_cpx-infected patients in Estonia in 2010. Aids Research and Human Retroviruses, 30 (3), 278−283.10.1089/aid.2012.0357.
1.1.
2014
Simmons, R.; Lutsar, I.; Malyuta, R.; Rosińska, M.; Porter, K. (2014). Using incidence assays within the context of the recent infections testing algorithm. AIDS, 28 (14), 2167−2167.10.1097/QAD.0000000000000367.
1.1.
2014
Nellis, G.; Lutsar, I.; Varendi, H.; Toompere, K.; Turner, MA.; Duncan, J.; Metsvaht, T. (2014). Comparison of two alternative study designs in assessment of medicines utilisation in neonates. BMC Medical Research Methodology, 14, 89−94. DOI: 10.1186/1471-2288-14-89.
1.1.
2014
Lutsar, I.; Telling, K.; Metsvaht, T. (2014). Treatment option for sepsis in children in the era of antibiotic resistance. Expert Review of Anti-infective Therapy, 12 (10), 1237−1252.10.1586/14787210.2014.956093.
1.1.
2014
Jõgi, P.; Oona, M.; Toompere, K.; Leedo, S.; Epstein, J.; Lutsar, I (2014). Seroprevalence of IgG antibodies to pertussis toxin in children andadolescents in Estonia. Vaccine, 32 (41), 5311−5315. DOI: 10.1016/j.vaccine.2014.07.066.
1.1.
2014
Drell, Tiina; Lutsar, Irja; Štšepetova, Jelena; Parm, Ülle; Metsvaht, Tuuli; Ilmoja, Mari-Liis; Simm, Jaak; Sepp, Epp. (2014). The development of gut microbiota in critically ill extremely low birth weigth infants assessed with 16S rRNA gene based sequencing. Gut Microbes, 5, 1−7.
1.2.
2014
Toome, Liis; Plado, Silvi; Ringmets, Inge; Vals, Mari-Anne; Varendi, Heili; Lutsar, Irja (2014). Respiratory infections in very low gestational age infants: a population-based cohort study in Estonia. Journal of Pediatric and Neonatal Individualized Medicine, 3 (1), 1−10. DOI: 10.7363/030115.
3.5.
2014
Mesek, Inge; Nellis, Georgi; Lass, Jana; Lutsar, Irja (2014). Euroopa neonatoloogia osakondades kasutatavate ravimvormide vastsündinutele sobilikkuse hindamine kardiovaskulaarsüsteemi ravimite näitel. Eesti Arst: Tartu Ülikooli arstiteaduskonna aastapäeva teaduskonverents, Tartu, 9.-10. okt.
5.2.
2014
Soeorg H, Huik K, Parm Ü, Ilmoja ML, Metsvaht T, Lutsar I. (2014). Vancomycin-heteroresistance in Staphylococcus epidermidis colonizing neonates in neonatal intensive care units. The 32nd Annual Meeting of the European Society for Paediatric Infectious Diseases, May 6-10, 2014, Dublin, Ireland..
5.2.
2014
Jõgi, P.; Oona, M.; Toompere, K.; Epstein, J.; Lutsar, I. (2014). Does the number of boosters and the diagnostic method influence the notification of pertussis? 32th Annual Meeting of the European Society for Paediatric Infectious Diseases. Dublin, Ireland, May 6-10..
5.2.
2014
Kogermann, K.; Putrinś, M.; Lippus, M.; Smidt, I.; Truusalu, K.; Lutsar, I.; Tenson, T. (2014). Monitoring bacterial persisters during E.coli infection development in mouse model. In: . CBM2014, Tartu, Estonia, 16.-19.10.2014.
1.1.
2013
Oeser, C; Lutsar, I; Metsvaht, T; Turner, MA; Heath, PT; Sharland, M (2013). Clinical trials in neonatal sepsis. Journal of Antimicrobial Chemotherapy, 68 (12), 2733−2745. DOI: 10.1093/jac/dkt297.
1.1.
2013
Garazzino, S; Lutsar, I; Bertaina, C; Tovo, PA; Sharland, M (2013). New antibiotics for paediatric use: A review of a decade of regulatory trials submitted to the European Medicines Agency from 2000-Why aren't we doing better? International Journal of Antimicrobial Agents, 42 (2), 99−118. DOI: 10.1016/j.ijantimicag.2013.05.001.
1.1.
2013
Soeorg, H.; Huik, K.; Parm, U.; Ilmoja, ML.; Metelskaja, N.; Metsvaht, T.; Lutsar, I. (2013). Genetic Relatedness of Coagulase-Negative Staphylococci from Gastrointestinal Tract and Blood of Preterm Neonates with Late-Onset Sepsis. The Pediatric Infectious Disease Journal, 32 (4), 389−393.10.1097/INF.0b013e3182791abd.
1.1.
2013
Quinlivan, M.; Sengupta, N.; Papaevangelou, V.; Sauerbrei, A.; Grillner, L.; Rousseva, R.; Hague, R.; Lutsar, I.; Jogi, P.; Leca, A.; Grytchol, R.; Alain, S.; Breuer, J. (2013). Use of oral fluid to examine the molecular epidemiology of varicella zoster virus in the United kingdom and continental europe. The Journal of Infectious Diseases, 207 (4), 588−593. DOI: 10.1093/infdis/jis649.
1.1.
2013
Turner, Mark; Duncan, Jennifer; Shah, Utpal; Metsvaht, Tuuli; Varendi, Heili, Nellis, Georgi; Lutsar, Irja; Vaconsin, Pascal; Storme, Thomas; Rieutord, Andre; Nunn, Anthony (2013). European Study of Neonatal Exposure to Excipients: An update. International Journal of Pharmaceutics, 457 (1), 357−358. DOI: 10.1016/j.ijpharm.2013.08.078.
1.1.
2013
Lodi, S; del Amo, J; d'Arminio Monforte, A; Abgrall, S; Sabin, C; Morrison, C; Furrer, H; Muga, R; Porter, K; Girardi, E (2013). Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax, 68 (3), 207−213.10.1136/thoraxjnl-2012-201740.
1.1.
2013
Touloumi, G; Pantazis, N; Pillay, D; Paraskevis, D; Chaix, ML; Bucher, HC; Kucherer, C; Zangerle, R; Kran, AM; Porter, K (2013). Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. Clinical Infectious Diseases, 56 (6), 888−897. DOI: 10.1093/cid/cis1000.
1.1.
2013
van der Helm, J; Geskus, R; Sabin, C; Meyer, L; Del Amo, J; Chene, G; Dorrucci, M; Muga, R; Porter, K; Prins, M (2013). Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after. Gastroenterology, 144 (4), 751−760.10.1053/j.gastro.2012.12.026.
1.1.
2013
Rosinska, M; Marzec-Bogustawska, A; Janiec, J; Smolen-Dzirba, J; Wasik, T; Gniewosz, J; Zalewska, M; Murphy, G; McKinney, E; Porter, K (2013). High percentage of recent HIV infection among HIV-positive individuals newly diagnosed at voluntary counseling and testing sites in Poland. Aids Research and Human Retroviruses, 29 (5), 805−813.10.1089/aid.2012.0314.
1.1.
2013
Madec, Y; Boufassa, F; Porter, K; Prins, M; Sabin, C; d'Arminio Monforte, A; Amornkul, P; Bartmeyer, B; Sannes, M; Venet, A; Lambotte, O; Meyer, L (2013). Natural history of HIV-control since seroconversion. AIDS, 27 (15), 2451−2460.10.1097/01.aids.0000431945.72365.01.
1.1.
2013
Lodi, S; Fisher, M; Phillips, A; De Luca, A; Ghosn, J; Malyuta, R; Zangerle, R; Moreno, S; Vanhems, P; Boufassa, F; Guiguet, M; Porter, K (2013). Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection. PLoS ONE, 8 (11), e78642.10.1371/journal.pone.0078642.
1.1.
2013
Versporten, A.; Sharland, M.; Bielicki, J.; Drapier, N.; Vankerckhoven, V.; Goossens, H.; ARPEC, Project Group Members (incl. Lutsar I). (2013). The antibiotic resistance and prescribing in European Children project: a neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide. The Pediatric Infectious Disease Journal, 32 (6), e242−e253.10.1097/INF.0b013e318286c612.
1.1.
2013
Brilene, T.; Soeorg, H.; Kiis, M.; Sepp, E.; Kõljalg, S.; Lõivukene, K.; Jürna-Ellam, M.; Kalinina, J.; Stšepetova, J.; Metsvaht, T.; Lutsar, I. (2013). In vitro synergy of oxacillin and gentamicin against coagulase-negative staphylococci from blood cultures of neonates with late-onset sepsis. Apmis, 121 (9), 859−864. DOI: 10.1111/apm.12048.
1.1.
2013
Huik, K; Avi, R; Pauskar, M; Kallas, E; Jõgeda, EL; Karki, T; Marsh, K; Des Jarlais, D; Uusküla, A; Lutsar, I (2013). Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users. Infection Genetics and Evolution, 20, 78−82.10.1016/j.meegid.2013.08.008.
1.1.
2013
Huik, K; Avi, R; Carrillo, A; Harper, N; Pauskar, M; Sadam, M; Karki, T; Krispin, T; He, W; Lutsar, I (2013). CCR5 Haplotypes Influence HCV Serostatus in Caucasian Intravenous Drug Users. PLoS ONE, 8 (7), e70561. DOI: 10.1371/journal.pone.0070561.
1.2.
2013
Standing, JF; Tsolia, M; Lutsar, I (2013). Pharmacokinetics and pharmacodynamics of oseltamivir in neonates, infants and children. Infectious Disorders - Drug Targets, 13 (1), 6−14.
1.2.
2013
Lass, J.; Odlind, V.; Irs, A.; Lutsar, I. (2013). Antibiotic prescription preferences in paediatric outpatient setting in Estonia and Sweden. SpringerPlus, 2, 124−x.10.1186/2193-1801-2-124.
1.2.
2013
Lill, M.; Kõks, S.; Soomets, U.; Schalkwyk, LC.; Fernandes, C.; Lutsar, I.; Taba, P. (2013). Peripheral blood RNA gene expression profiling in patients with bacterial meningitis. Frontiers in Neuroscience, 7, 33.10.3389/fnins.2013.00033.
5.2.
2013
Turner, M.; Yakkundi, S.; Varendi, H.; Metsvaht, T.; Nellis, G.; Windrow, J.; Graham, S.; Mulla, H.; Pandya, H.; Tapscott, S.; Caldwell, N.; Duncan, J.; Lutsar, I.; McElnay, J. (2013). Methyl and propyl paraben concentrations in blood from preterm neonates exposed to clinically indicated medicines are lower than the concentrations of these anti-microbial excipients reported to affect cell physiology. 14th Biannual Congress of the European Society for Developmental Perinatal and Pediatric Pharmacology (EDPPP), Salzburg, Austria, 04.-07.06.2013.
5.2.
2013
Nellis, G.; Metsvaht, T.; Lass, J.; Varendi, H.; Turner, M.; Lutsar, I. (2013). European Study of Neonatal Excipient Exposure (ESNEE): preliminary results of the point prevalence survey. 14th Biannual Congress of the European Society for Developmental Perinatal and Pediatric Pharmacology (EDPPP), Salzburg, Austria, 04.-07.06.2013.
1.1.
2012
Jarrin, I; Pantazis, N; Gill, MJ; Geskus, R; Perez-Hoyos, S; Meyer, L; Prins, M; Touloumi, G; Johnson, A; Hamouda, O; de Olalla, PG; Porter, K; del Amo, J (2012). Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clinical Infectious Diseases, 54 (1), 111−118. DOI: 10.1093/cid/cir814.
1.1.
2012
Pulcini, C; Bush, K; Craig, WA; Frimodt-Moller, N; Grayson, ML; Mouton, JW; Turnidge, J; Harbarth, S; Gyssens, IC (2012). Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clinical Infectious Diseases, 54 (2), 268−274. DOI: 10.1093/cid/cir838.
1.1.
2012
Pantazis, N; Morrison, C; Amornkul, PN; Lewden, C; Salata, RA; Minga, A; Chipato, T; Jaffe, H; Lakhi, S; Karita, E; Porter, K; Meyer, L; Touloumi, G (2012). Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS ONE, 7 (3), e32369.10.1371/journal.pone.0032369.
1.1.
2012
Zugna, D; Geskus, RB; De Stavola, B; Rosinska, M; Bartmeyer, B; Boufassa, F; Chaix, ML; Babiker, A; Porter, K (2012). Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection. Antivir Ther 17:1039-1048. Antiviral Therapy, 17 (6), 1039−1048.10.3851/IMP2312.
1.1.
2012
Huang, X.; Lodi, S.; Fox, Z.; Li, W.; Phillips, A.; Porter, K.; Lutsar, I.; Kelleher, A.; Li, N.; Xu, X.; Wu, H.; Johnson, AM. (2012). Rate of CD4 decline and HIV-RNA change following HIV Seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. Jaids-Journal of Acquired Immune Deficiency Syndromes, 62 (4), 441−446.10.1097/QAI.0b013e31827f5c9a.
1.1.
2012
Lass, J.; Naelapää, K.; Shah, U.; Käär, R.; Varendi, H.; Turner, MA.; Lutsar, I. (2012). Hospitalised neonates in Estonia commonly receive potentially harmful excipients. BMC Pediatrics, 12, 136.10.1186/1471-2431-12-136.
1.1.
2012
Padari, H.; Metsvaht, T.; Kõrgvee, LT.; Germovsek, E.; Ilmoja, ML.; Kipper, K.; Herodes, K.; Standing, JF.; Oselin, K.; Lutsar, I. (2012). Short versus Long Infusion of Meropenem in Very-Low-Birth-Weight Neonates. Antimicrobial Agents and Chemotherapy, 56 (9), 4760−4764.10.1128/AAC.00655-12.
1.1.
2012
Esposito, S.; Cohen, R.; Domingo, JD.; Pecurariu, OF.; Greenberg, D.; Heininger, U.; Knuf, M.; Lutsar, I.; et, al. (2012). Antibiotic Therapy for Pediatric Community-Acquired Pneumonia: Do We Know When, What and For How Long to Treat? The Pediatric Infectious Disease Journal, 31 (6), e78−e85.10.1097/INF.0b013e318255dc5b.
1.1.
2012
Soeorg, H.; Tamm, E.; Huik, K.; Pauskar, M.; Mägi, D.; Pruudel, K.; Vainomäe, L.; Moosar, L.; Kirss, K.; Torm, S.; Närska, M.; Pütsepp, A.; Nurm, H.; Pruunsild, K.; Jänes, A.; Zilmer, K.; Lutsar, I. (2012). Group A rotavirus genotypes circulating prior to implementation of a National Immunization Program in Estonia. Human Vaccines, 8 (4), 465−469.10.4161/hv.19135.
1.2.
2012
Tamme, Kadri; Minajeva, Ave;, Adamson, Vivika; Ristmägi, Kaarina; Põder, Jaak; Lutsar, Irja (2012). Clinical Findings and Pathologic Changes Associated with Fatal Cases of 2009/2010 Pandemic Influenza A/H1N1 Viral Infection in Estonia. A Retrospective Study. Medicina (Kaunas), 48 (1), 48−56.
1.3.
2012
Jõgi, P.; Oona, M.; Tamm, E.; Lutsar, I. (2012). Läkaköha nüüdisaegne diagnostika. Eesti Arst, 91 (1), 19−25.
1.3.
2012
Prükk, T.; Maimets, M.; lutsar, I. (2012). Lyme’i tõve nüüdisaegne diagnostika ja ravi. Eesti Arst, 91 (2), 141−147.
5.2.
2012
Lass, Jana; Metsvaht, Tuuli; Nellis, Georgi; Lutsar, Irja (2012). The comparability of different study methodologies for evaluating antibiotic consumption in neonatal intensive care units (NICU). ESPID.
5.2.
2012
Nellis, Georgi; Varendi, Heili; Lass, Jana; Lutsar, Irja; Metsvaht, Tuuli. (2012). Antibiotic prescribing in European neonatal intensive care units: service evaluation study of the European study of neonatal exposure to excipients. Eesti Arst: TÜ Arstiteaduskonna päev, okt.2012. , 11. (91).
5.2.
2012
Nellis, Georgi; Varendi, Heili; Lass, Jana; Lutsar, Irja; Metsvaht, Tuuli. (2012). Potentially Harmful Excipients in Antibiotics Prescribed to European Neonates - ESNEE Survey. Acta Médica Portuguesa: 3rd International Congress of UENPS, 2012; Porto, nov 14-17. , 141. (25; 2).
5.2.
2012
Varendi, Heili; Nellis, Georgi; Metsvaht, Tuuli; Lass, Jana; Lutsar, Irja. (2012). European Study of the Neonatal Exposure to Excipients: Results of the Survey, Enterally Administered Products. Acta Médica Portuguesa : 3rd International Congress of UENPS 2012; Porto, nov 14-17. Portugal, 141−142. (25; S2).
1.1.
2011
Yakkundi, Shirish; McElnay, James; Millership, Jeff; Mulla, Hussain; Pandya, Hitesh; Shah, Utpal; Nunn, Tony; Rieutord, Andre; Storme, Thomas; Vasconsin, Pascal; Metsvaht, Tuuli; Varendi, Heili; Nellis, Georgi; Lutsar, Irja; Turner, Mark. (2011). Use of dried blood spots to study excipient kinetics in neonates. Bioanalysis, 3 (24), 2691−2693. DOI: 10.4155/BIO.11.277.
1.1.
2011
Lutsar, I.; Trafojer, UM.; Heath, PT.; Metsvaht, T.; Standing, J.; Esposito, S.; de Cabre, VM.; Oeser, C.; Aboulker, JP. (2011). Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial. Trials, 12, 215.10.1186/1745-6215-12-215.
1.1.
2011
Metsvaht, T.; Ilmoja, ML.; Parm, U.; Merila, M.; Maipuu, L.; Müürsepp, P.; Julge, K.; Sepp, E.; Lutsar, I. (2011). Ampicillin versus penicillin in the empiric therapy of ELBW neonates at risk of early onset sepsis. Pediatrics International, 5 (53), 873−880.
1.1.
2011
Freire-Moran, L.; Aronsson, B.; Manz, C.; Gyssens, IC.; So, AD.; Monnet, DL.; Cars, O.; ECDC-EMA Working Group (incl. Lutsar, I.) (2011). Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. Drug Resistance Updates, 14, 118−124.
1.1.
2011
Parm, U.; Metsvaht, T.; Sepp, E.; Ilmoja, ML.; Pisarev, H.; Pauskar, M.; Lutsar, I. (2011). Mucosal surveillance cultures in predicting Gram-negative late-onset sepsis in neonatal intensive care units. Journal of Hospital Infection, 78 (4), 327−332. DOI: 10.1016/j.jhin.2011.03.025.
1.1.
2011
Lass, Jana; Käär, Ruth; Jõgi, Kaarin; Varendi, Heili; Metsvaht, Tuuli; Lutsar, Irja (2011). Drug utilisation pattern and off-label use of medicines in Estonian neonatal units. European Journal of Clinical Pharmacology, 12 (67), 1263-1271−1271. DOI: 10.1007/s00228-011-1072-x.
1.1.
2011
Mussini, C; Cossarizza, A; Sabin, C; Babiker, A; De Luca, A; Bucher, HC; Fisher, M; Rezza, G; Porter, K; Dorrucci, M (2011). Decline of CD4(+) T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals. AIDS, 25 (8), 1041−1049.10.1097/QAD.0b013e3283463ec5.
1.1.
2011
van der Helm, JJ; Prins, M; del Amo, J; Bucher, HC; Chene, G; Dorrucci, M; Gill, J; Hamouda, O; Sannes, M; Porter, K; Geskus, RB (2011). The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS, 25 (8), 1083−1091.10.1097/QAD.0b013e3283471cce.
1.1.
2011
Jaffe, HW; De Stavola, BL; Carpenter, LM; Porter, K; Cox, DR (2011). Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. AIDS, 25 (11), 1395−1403.10.1097/QAD.0b013e3283489c8b.
1.1.
2011
Lutsar, Irja (2011). Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Archives of Internal Medicine, 171 (17), 1560−1569. DOI: 10.1001/archinternmed.2011.401.
1.1.
2011
Parm, U.; Metsvaht, T.; Sepp, E.; Ilmoja, ML.; Pisarev, H.; Pauskar, M.; Lutsar, I. (2011). Risk factors associated with gut and nasopharyngeal colonization by common Gram-negative species and yeasts in neonatal intensive unit patients. Early Human Development, 87 (6), 391−399.10.1016/j.earlhumdev.2011.02.007.
1.1.
2011
Lass, J.; Irs, A.; Pisarev, H.; Leinemann, T.; Lutsar, I. (2011). Off label use of prescription medicines in children in outpatient setting in Estonia is common. Pharmacoepidemiology and Drug Safety, 20 (5), 474−481.10.1002/pds.2125.
1.1.
2011
Heidmets, LT.; Metsvaht, T.; Ilmoja, ML.; Pisarev, H.; Oselin, K.; Lutsar, I. (2011). Blood Loss Related to Participation in Pharmacokinetic Study in Preterm Neonates. Neonatology, 100 (2), 111−115.
1.1.
2011
Avi, R; Huik, K; Pauskar, M; Ustina, V; Karki, T; Krispin, T; Ainsalu, K; Paap, P; Schmidt, J; Nikitina, N; Lutsar, I. (2011). Emerging Transmitted Drug Resistance in Treatment Naive Human Immunodeficiency Virus - 1 CRF06_cpx Infected Patients in Estonia. Scandinavian Journal of Infectious Diseases, 43 (2), 122−128.
1.2.
2011
Knellwolf, A.L.; Bauzon, S.; Della Casa Alberighi, O.; Lutsar, I.; Bacsy, E.; Alfarez, D.; Panei, P. (2011). Framework conditions facilitating paediatric clinical research. Italian Journal of Pediatrics, 37, 12. DOI: 10.1186/1824-7288-37-12.
1.3.
2011
Müürsepp, P.; Kõivumägi, K.; Kumm, ML.; Zilmer, K.; Lutsar, I. (2011). Tuulerõuged laste ja noorukite hospitaliseerimise põhjusena Eestis aastatel 2000–2005 [Varicella-related hospitalisations among children and adolescents in Estonia in the pre-vaccine era from 2000 to 2005]. Eesti Arst, 91 (1), 27−32.
5.1.
2011
Lill, M.; Lutsar, I.; Taba, P. (2011). Community-acquired bacterial meningitis in Estonia 2008-2009. EUROPEAN JOURNAL OF NEUROLOGY, 18: 15th Congress of the European-Federation-of-Neurological-Societies (EFNS) Location: Budapest, HUNGARY Date: SEP 10-13, 2011. 476. (SI 2).
5.2.
2011
Standing, J.; Morris, J.; Germovsek, E.; Lutsar, I.; Cortina-Borja, M. (2011). Methods for Optimising Neonatal Antimicrobial Use: Time- and Concentration-Dependent Agents. Page Conference, Athens 2011.
1.1.
2010
Wolbers, M; Babiker, A; Sabin, C; Young, J; Dorrucci, M; Chene, G; Mussini, C; Porter, K; Bucher, HC (2010). Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies. PLoS Medicine, 7 (2), e1000239.10.1371/journal.pmed.1000239.
1.1.
2010
Walsh, T.J.; Driscoll, T.; Milligan, P.A.; Wood, N.D.; Schlamm, H.; Groll, A.H.; Jafri, H.; Arrieta, A.C.; Klein, N.J.; Lutsar, I. (2010). Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrobial Agents and Chemotherapy, 54 (10), 4116−4123.10.1128/AAC.00896-10.
1.1.
2010
Parm, Ü.; Metsvaht, T.; Sepp, E.; Ilmoja, ML.; Pisarev, H.; Pauskar, M.; Lutsar, I. (2010). Impact of empiric antibiotic regimen on bowel colonization in neonates with suspected early onset sepsis. European Journal of Clinical Microbiology & Infectious Diseases, 29 (7), 807−816. DOI: 10.1007/s10096-010-0931-1.
1.1.
2010
Avi, R.; Huik, K.; Sadam, M.; Karki, T.; Krispin, T.; Ainsalu, K.; Paap, P.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2010). Characterization of Integrase Region Polymorphisms in HIV-1 CRF06_cpx Viruses in Treatment Naïve Patients in Estonia. Aids Research and Human Retroviruses, 26 (10), 1109−1113.10.1089/aid.2010.0097.
1.1.
2010
Lutsar, I.; Metsvaht, T. (2010). Understanding pharmacokinetic/pharmacodynamic in managing neonatal sepsis. Current Opinion in Infectious Diseases, 23 (3), 201−207.
1.1.
2010
Metsvaht, T.; Ilmoja, ML.; Parm, Ü.; Maipuu, L.; Merila, M.; Lutsar, I. (2010). Comparison of ampicillin plus gentamicin vs. penicillin plus gentamicin in empiric treatment of neonates at risk of early onset sepsis. Acta Paediatrica, 99 (5), 665−672.10.1111/j.1651-2227.2010.01687.x.
1.1.
2010
Huik, K.; Sadam, M.; Karki, T.; Avi, R.; Krispin, T.; Paap, P.; Rüütel, K.; Uusküla, A.; Talu, A.; Abel-Ollo, K.; Lutsar, I. (2010). CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users. The Journal of Infectious Diseases, 730−739.
3.2.
2010
Lutsar, I; Friedland, I. (2010). Clinical Trials of Anti-Infective Agents in Paediatrics. In: Rose, Klaus; van den Anker, John N. (Ed.). Guide to Paediatric Drug Development (170−177). . Basel, Switzerland: Karger. DOI: 10.1159/000315588.
5.2.
2010
Lill, M.; Kõks, S.; Soomets, U.; Schalkwyk, LC.; Fernandes, C.; Lutsar, I., Taba, P. (2010). Peripheral blood RNA gene expression profiling in the patients with community-acquired bacterial meningitis. In: (x).20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 10 - 13 April.
1.1.
2009
Brown, AE.; Gifford, RJ.; Clewley, JP.; Kucherer, C.; Masquelier, B.; Porter, K.; Balotta, C.; Back, NK.; Jorgensen, LB.; de Mendoza, C.; Bhaskaran, K.; Gill, ON.; Johnson, AM.; Pillay, D.; CASCADE Collaboration including Lutsar, I. (2009). Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions. The Journal of Infectious Diseases, 199 (3), 427−431.
1.1.
2009
Prymula, R; Anca, I; André, F; Bakir, M; Czajka, H; Lutsar, I; Mészner, Z; Salman, N; Simurka, P; Usonis, V. (2009). Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines. European Journal of Pediatrics, 168, 1031−1035.
1.1.
2009
Avi, R; Huik, K; Sadam, M; Karki, T; Krispin, T; Ainsalu, K; Paap, P; Schmidt, J; Nikitina, N; Lutsar, I. (2009). Absence of Genotypic Drug Resistance and Presence of Several Naturally Occurring Polymorphisms of Human Immunodeficiency Virus-1 CRF06_cpx in Treatment-Naive Patients in Estonia. Journal of Medical Virology, 81 (6), 953−958. DOI: 10.1002/jmv.21482.
1.1.
2009
Karlsson, MO.; Lutsar, I.; Milligan, PA. (2009). A population pharmacokinetic of voriconazole plasma concentration data from pediatric studies. Antimicrobial Agents and Chemotherapy, 53 (3), 935−944. DOI: 10.1128/AAC.00751-08.
1.1.
2009
Lutsar, I.; Anca, I.; Bakir, M.; Usonis, V.; Prymula, R.; Salman, N.; Grezesiowski, P.; Greenberg, M. (2009). Epidemiological characteristics of pertussis in Estonia, Lithuania, Romania, the Czech Republic, Poland and Turkey-1945 to 2005. European Journal of Pediatrics, 168, 407−415. DOI: 10.1007/s00431-008-0754-6.
1.1.
2009
Metsvaht, T.; Pisarev, H.; Ilmoja, ML.; Parm, U.; Maipuu, L.; Merila, M.; Muursepp, P.; Lutsar, I. (2009). Clinical parameters predicting failure of empirical antibacterial therapy in early onset neonatal sepsis, identified by classification and regression tree analysis. BMC Pediatrics, 9, 72. DOI: 10.1186/1471-2431-9-72.
1.3.
2009
Lutsar, I.; Metsvaht, T.; Tamm, E. (2009). Meningokokiline infektsioon lastel ja täiskasvanutel. Eesti Arst, 88 (1), 28−40.
5.2.
2009
Huik, K.; Avi, R.; Sadam, M.; Karki, T.; Denks, K.; Krispin, T.; Ustina, V.; Rüütel, K.; Uusküla, A.; Murphy, G.; Lutsar, I. (2009). Performance of the BED-CEIA in population infected with HIV1 recombinant viruses CRF06cpx and CRF06A. Clinical Microbiology and Infection: 19th European Congress of Clinical Microbiology and Infectious Diseases Helsinki, Finland, 16 - 19 May 2009.
6.3.
2009
Lutsar Irja, Lass Jana (2009). Ravimite kasutamine lastel. Lege Artis, 5, 42−45.
1.1.
2008
Jarrin, I.; Geskus, R.; Bhaskaran, K.; Prins, M.; Perez-Hoyos, S.; Muga, R.; Hernández-Aguado, I.; Meyer, L.; Porter, K.; del Amo, J.; Group author CASCADE Collaboration, (incl. I.Lutsar). (2008). Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. American Journal of Epidemiology, 168 (5), 532−540. DOI: 10.1093/aje/kwn179.
1.1.
2008
Bhaskarran, K.; Hamouda, O.; Sannes, M.; Bonfassa, F.; Johnson, A.M.; Lambert, P.C.; Porter, K.; CASCADE, Collaboration (2008). Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population. JAMA : the journal of the American Medical Association, 300 (1), 51−59.
1.1.
2008
Touloumi, G.; Pantazis, N.; Stirnadel, HA.; Walker, AS.; Boufassa, F.; Vanhems, P.; Porter, K.; Cascade including Lutsar, I. (2008). Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice. Jaids-Journal of Acquired Immune Deficiency Syndromes, 49 (5), 492−498.
1.1.
2008
Pantazis, N.; Touloumi, G.; Vanhems, P.; Gill, J.; Buchere, HC.; Porter, K.; CASCADE Collaboration (incl. Lutsar, I.) (2008). The effect of antiretroviral treatment of different durations in primary HIV infection. AIDS, 22 (18), 2441−2450. DOI: 10.1097/QAD.0b013e328319ea4e.
1.1.
2008
Meriste, S.; Jacquet, J.-M.; Willems, P.; Lutsar, I. (2008). Immunologic response to Hib tetanus toxoid conjugated vaccine coadministered with DTPa either mixed or in two separate injections in toddlers not primed with Hib vaccine. Human Vaccines, 4 (1), 31−35.
1.1.
2008
Troke, P.; Aguirrebengoa, K.; Arteaga, C.; Ellis, D.; Heath, C.; Lutsar, I.; Rovira, M.; Nguyen, Q.; Slavin, M.; Chen, S. (2008). Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients. Antimicrobial Agents and Chemotherapy, 52 (5), 1743−1750.
5.2.
2008
Uudelepp, ML.; Tamm, E.; Torm, S.; Urbsoo, K.; Pruunsild, K.; Part, R.; Lutsar, I. (2008). Bacterial meningitis in children in Estonia in 1980-1989 and 1998-2007. 17th ESPID; Graz, Austria; 13-17 May 2008.
5.2.
2008
Merila, M.; Metsvaht, T.; Parm, Ü.; Maipuu, L.; Müürsepp, P.; Lutsar, I. (2008). Maternal risk-factors of need for early change of empirical antibacterial treatment in neonates with high risk of sepsis. In: . 26th ESPID; Graz, Austria; 13-17 May 2008.
5.2.
2008
Eimra, K.; Parm, Ü.; Metsvaht, T.; Ilmoja, ML.; Lutsar, I. (2008). Genotypic Relatedness of Candida spp. in Two NICU-s in Estonia. 26. European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 19-22 Apr 2008.
5.2.
2008
Parm, Ü.; Sepp, E.; Metsvaht, T.; Ilmoja, ML.; Pruunsild, K.; Maipuu, L.; Kõljag, S.; Makoid, E.; Lutsar, I. (2008). The association between mucosal colonisation with opportunistic pathogens and blood stream infections in the two NICUs in Estonia. 26. European Congress of Clinical Microbiology and Infectious Diseases; Barcelona; 19-22 Apr 2008.
5.2.
2008
Metsvaht, T.; Ilmoja, M.-L.; Parm, Ü.; Merila, M.; Maipuu, L.; Sepp, E.; Müürsepp, P.; Lutsar, I. (2008). Management of Early Onset Neonatal Sepsis (EOS): comparative study of ampicillin (AMP) vs penicillin (PEN) in combination with gentamicin (GEN). International Conference of Antimicrobial Agents and Chemotherapy; Washington; 24-28 Oct 2008.
5.2.
2008
Truusalu, K.; Kõljalg, S.; Parm, Ü.; Sepp, E.; Metsvaht, T.; Naaber, P.; Lõivukene, K.; Lutsar, I. (2008). Staphylococcal Infection and Colonization of Pediatric Intensive Care Unit Patients: MRSA versus MRSE. Abstract book: Emerging Technologies of Medical Importance for the Diagnosis of Infectious Diseases and the Detection of Pathogenic Microbes. 1 st Intenational ASM Conference in Bejing, April 6-10, 2008. , 44.
5.2.
2008
Mitt, P.; Adamson, V.; Truusalu, K.; Parm, Ü.; Kõljalg, S.; Sepp, E.; Lõivukene, K.; Lutsar, I.; Maimets, M. (2008). An outbreak of meticillin-resistant Staphylococcus aureus (spa type t008) in the paediatric intensive care unit of a university hospital, Tartu. Clinical Microbiology and Infection, 14: 18th European Congress of Clinical Microbiology and Infectious Diseases. , Abstract number: P1439. (S7).
5.2.
2008
Huik, K.; Avi, R.; Sadam, M.; Karki, T.; Albert, J.; Lutsar, I. (2008). Drug Resistance Mutations in HIV-1 CRF06_cpx Viruses Isolated from Treatment Naïve and Experienced Patients. European Journal of Medical Research: 19th European Students’ Conference; Berlin; 28 September - 3 October 2008.
5.2.
2008
Avi, R.; Huik, K.; Karki, T.; Sadam, M.; Krispin, T.; Ainsalu, K.; Paap, P.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2008). Drug Resistance Mutations and Genetic Barrier for Drug Resistance Development in Estonian HIV-1 CRF06_cpx Integrase Sequences. 14th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology; Cape Town, South Africa; 1-5 September 2008.
5.2.
2008
Avi, R.; Huik, K.; Sadam, M.; Karki, T.; Krispin, T.; Paap, P.; Ainsalu, K.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2008). Natural polymorphisms associated with integrase inhibitor drug resistance in Estonian HIV-1 CRF06_cpx strains. 18th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona; 19.04-22.04.2008.
5.2.
2008
Sadam, M.; Karki, T.; Huik, K.; Avi, R.; Rüütel, K.; Uusküla, A.; Lutsar, I (2008). CCL3L1 Variable Gene Copy Number Influence on the Susceptibility to HIV-1/AIDS Among Estonian Intravenous Drug User. The 15th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, 03.02-06.02.2008.
1.1.
2007
Tamm, E.; Naaber, P.; Maimets, M.; Oona, M.; Kõljalg, S.; Lutsar, I. (2007). Antimicrobial susceptibility and serogroup/serotype distribution of nasopharyngeal isolates of Streptococcus pneumoniae in healthy Estonian children in 1999-2003. Clinical Microbiology and Infection, 13 (8), 824−826. DOI: 10.1111/j.1469-0691.2007.01743.x.
1.1.
2007
Metsvaht, T.; Oselin, K.; Ilmoja, M.; Anier, K.; Lutsar, I. (2007). Pharmacokinetics of penicillin G in very-low-birth-weight neonates. Antimicrobial Agents and Chemotherapy, 51 (6), 1995−2000.
1.3.
2007
Sergejev, M.; Lutsar, I. (2007). Gripivastased ravimid. Eesti Arst, 86 (2), 82−84.
5.1.
2007
Denks, K.; Huik, K.; Avi, R.; Sadam, M.; Krispin, T.; Lutsar, I. (2007). GB virus C infection among HIV-positive patients in Estonia. International Journal of Antimicrobial Agents, 29 (3), S155−S155.
5.1.
2007
Avi, R.; Huik, K.; Karki, T.; Sadam, M.; Paap, P.; Smidt, J.; Ainsalu, K.; Krispin, T.; Lutsar, I (2007). The coexistence of secondary PR mutations M36I, K20I and L63H predominates in CRF06_cpx and its next generation recombinant virusese circulating in Estonian treatment naive patients. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 29. S549−S549.
5.2.
2007
Parm, Ü., Sepp, E., Metsvaht, T., Ilmoja, M.L.., Lutsar, I. (2007). Oportunistlike mikroobide esinemine intensiivravi osakonnas viibivatel vastsündinutel. Eesti Arst, 86: Õppejõudude, teadurite, doktorantide, magistrantide ja üliõpilaste teaduskonverents 18. oktoobril 2007 TÜ Biomeedikumis. Eesti Arst, 673. (9).
6.2.
2007
Lutsar, I.; Mikelsaar, M.; Karki, T. (2007). Meditsiiniline mikrobioloogia II. Tartu: Tartu Ülikooli Kirjastus.
1.1.
2006
Meriste, S.; Lutsar, I.; Tamm, E.; Willems, P. (2006). Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine. Scandinavian Journal of Infectious Diseases, 38 (5), 350−356.
1.3.
2006
Meriste, S.; Oona, M.; Tamm, E.; Lutsar, I. (2006). Immuniseerimisega välditavate nakkushaiguste levik ja preventsioon Euroopas ja Eestis. Eesti Arst, 85 (2), 107−126.
6.2.
2006
Mikelsaar, M.; Karki, T.; Lutsar, I.; Mändar, R. (2006). Meditsiiniline mikrobioloogia I [Medical Microbiology Vol.1.]. Tartu: Tartu Ülikooli Kirjastus.
1.1.
2005
Mouas, H.; Lutsar, I.; Dupont, B.; Fain, O.; Herbrecht, R.; Lescure, F.; Lorthorlary, O. (2005). Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clinical Infectious Diseases, 40 (8), 1141−1147.
1.1.
2005
Usonis, V.; Meriste, S.; Bakasenas, V.; Lutsar, I.; Collard, F.; Stoffeld, A.; Tornieporth, N. (2005). Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months. Vaccine, 23 (20), 2602−2606.
1.1.
2005
Schwartz, S.; Ruhnke, M.; Ribaud, P.; Corey, L.; Driscoll, T.; Cornely, OA.; Schuler, U.; Lutsar, I.; Troke, P.; Thiel, E. (2005). Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood, 106 (8), 2641−2645.
1.3.
2005
Lutsar, I. (2005). HI-viirusinfektsioon kui globaalne probleem. Eesti Arst, 4, 238−243.
3.3.
2005
Lutsar, I.; Tamm, E.; Metsvaht, T.; Roos, R. (2005). Antimikroobsete ravimite manustamine lastele. Tallinn: Medicina.
5.2.
2005
Roos, R.; Adamson, V.; Lutsar, I.; Metsvaht, T. (2005). Antibiootikumide (AB) tarbimise ja koormuse hindamine TÜ Kliinikumi lasteintensiivravi osakonnas: modifitseeritud DDD-metoodika. Eesti Arst, 84. 679−679. (9).
5.2.
2005
Metsvaht, T.; Padari, H.; Lutsar, I. (2005). Ampitsilliin-gentamütsiin versus penitsilliin-gentamütsiin varase empiirilise antibakteriaalse ravi valikuna vastsündinutel. Eesti Arst, 84. Eesti Arst, 672−673. (9).
1.1.
2004
Walsh, T.J.; Karlsson, M.O.; Driscoll, T.; Arguedas, A.G.; Adamson, P.; Saez-Llorens, X.; Vora, A.J.; Arrieta, A.C.; Blumer, J.; Lutsar, I.; Milligan, P.; Wood, N. (2004). Pharmacokinetics and safety of intrevenous voriconazole in children after single and multiple dose administration. Antimicrobial Agents and Chemotherapy, 48 (6), 2166−2172.
1.1.
2004
Steinbach, W.J.; Benjamin, D.K.; Kontoyiannis, D.P.; Perfect, J.R.; Lutsar, I.; Marr, K.A.; Lionakis, M.S.; Torres, H.A.; Jafri, H.; Walsh, T.J. (2004). Infections due to Aspergillus terreus: multicenter retrospective analysis of 83 cases. Clinical Infectious Diseases, 39, 192−198.
1.1.
2003
Lutsar, I.; Roffey, S.; Troke, P. (2003). Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clinical Infectious Diseases, 37 (5), 728−732.
1.1.
2003
Lutsar, I.; Hodges, MR.; Tomaszewski, K.; Troke, PF.; Wood, ND. (2003). Safety of voriconazole and dose individualisation. Clinical Infectious Diseases, 36 (8), 1087−1088.
1.1.
2003
Lutsar, I.; Friedland, IR.; Wubbel, L.; Ahmed, A.; Truijllo, M.; McCoig, CC.; Jafri, HH.; McCracken, GH.Jr. (2003). Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis. Journal of Antimicrobial Chemotherapy, 52 (4), 651−655.
1.1.
2003
Perfect, JR.; Marr, KA.; Walsh, TJ.; Greenberg, RN.; Dupont, B.; De La Torre-Cisneros, J.; Just-Nübling, G.; Schlamm, H.; Lutsar, I.; Espinel-Ingroff, A.; Johnson, E. (2003). Voriconazole treatment for less common, emerging or refractory fungal infections. Clinical Infectious Diseases, 36 (9), 1122−1131.
1.3.
2003
Tamm, E.; Kõljalg, S.; Lutsar, I.; Maimets, M.; Naaber, P. (2003). Pneumokokkinfektsioon lapseeas. Eesti Arst, 82 (7), 464−471.
1.1.
2002
Walsh, TJ.; Lutsar, I.; Driscoll, T.; Dupont, B.; Roden, M.; Ghahramani, P.; Hodges, M.; Groll, AH.; Perfect, JR. (2002). Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. The Pediatric Infectious Disease Journal, 21 (3), 240−248.
1.1.
2000
Lutsar, I.; Friedland, IR. (2000). Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clinical Pharmacokinetics, 39 (5), 335−343.
1.1.
2000
Ng, W.; Olsen, K.; Lutsar, I.; Wubbel, L.; Ghaffar, F.; Jafri, H.; McCracken, GH.; Friedland, I. (2000). Buffy coat PCR for diagnosis of experimental pneumococcal pneumonia. Apmis, 108 (11), 729−733.
1.1.
1999
Meriste, S.; Tamm, E.; Willems, P.; Lutsar, I. (1999). Safety and immunogenicity of combined DTPa-IPV for primary and booster vaccination. Scandinavian Journal of Infectious Diseases, 31 (6), 587−591.
1.1.
1999
Ahmed, A.; Jafri, H.; Lutsar, I.; McCoig, CC.; Trujillo, M.; Wubbel, L.; Shelton, S.; McCracken, GH. (1999). Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrobial Agents and Chemotherapy, 43 (4), 876−881.
1.1.
1999
Lutsar, I.; Friedland, IR.; Jafri, HS.; Wubbel, L.; Ng, W.; Ghaffar, F.; McCracken, GH.Jr. (1999). Efficacy of gatifloxacin in experimental Escherichia coli meningitis. Antimicrobial Agents and Chemotherapy, 43 (7), 1805−1807.
1.1.
1999
McCoig, CC.; Friedland, IR.; Lutsar, I.; Jafri, HS.; Wubbel, L.; Olsen, K.; Shelton, S.; McCracken, GH.Jr. (1999). Pharmacodynamics and bactericidal activity of trovafloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis. Journal of Antimicrobial Chemotherapy, 43 (5), 683−688.
1.1.
1999
Ng, W.; Lutsar, I.; Wubbel, L.; Jafri, H.; Ghaffar, F.; McCracken, GH.Jr.; Friedland, IR. (1999). Pharmacodynamics of trovafloxacin in the cephalosporin-resistant pneumococcal pneumonia in immunocompetent mice. Journal of Antimicrobial Chemotherapy, 43 (6), 811−816.
1.1.
1998
Lutsar, I.; Friedland, I.; Wubbel, L.; McCoig, C.; Jafri, H.; Ghaffar, F.; McCracken, G. (1998). Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents and Chemotherapy, 42 (10), 2650−2655.
1.1.
1998
Lutsar, I.; McCracken, GH.; Friedland, IR. (1998). Antibiotic pharmacodynamics in cerebrospinal fluid. Clinical Infectious Diseases, 27 (5), 1117−1127.
1.2.
1998
Friedland, IR.; Lutsar, I. (1998). New Antibiotics. Current Opinion in Pediatrics, 10 (1), 41−45.
1.1.
1997
Lutsar, I.; Ahmed, A.; Friedland, IR.; Trujillo, M.; Wubbel, L.; Olsen, K.; McCracken, GH. (1997). Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrobial Agents and Chemotherapy, 41 (11), 2414−2417.
1.2.
1997
Lutsar, I.; Friedland, IR.; McCracken, GH.Jr. (1997). Pathogenesis of bacterial meningitis. Annales Nestle, 55, 92−102.
1.1.
1996
Siigur, U.; Tamm, E.; Torm, S.; Lutsar, I.; Salminen, S. (1996). Effect of bacterial infection and administration of a probiotic on fecal short-chain fatty acids. Microbial Ecology in Health and Disease, 9 (6), 271−277.
1.1.
1995
Lutsar, I.; Gontmacher, A.; Närska, M.; Rüütel, V.; Topman, M.; Ilves, P.; Siirde, T.; Beilmann, A. (1995). Five days of antibacterial therapy for bacterial meningitis in children. Infection, 23 (2), 113−118.
1.1.
1995
Lutsar, I.; Siirde, T.; Soopold, T. (1995). Long term follow-up of Estonian children after bacterial meningitis. The Pediatric Infectious Disease Journal, 14 (7), 624−625.
1.2.
1995
Sepp, E.; Tamm, E.; Torm, S.; Lutsar, I.; Mikelsaar, M.; Salminen, S. (1995). Impact of a lactobacillus probiotic on the faecal microflora in children with shigellosis. Microecology and Therapy, 23, 74−80.
1.1.
1994
Lutsar, I.; Haldre, S.; Topman, M.; Talvik, T. (1994). Enzymatic changes in the cerebrospinal-fluid in patients with infections of the central-nervous-system. Acta Paediatrica, 83 (11), 1146−1150.
19.03.2021

Otsi projekti

  • {{item.Name}}
Asutus on projekti finantseerija   Asutus on projekti teostaja  
  • {{searchListItem.Name}}
Kõik   Tavaprojektid   Ülemprojektid   Alamprojektid  
Uus Frascati (2015)
Uus ja vana Frascati (otsing uue järgi väljastab ka seotud vanad)
Kõik
Käimasolevad
Lõppenud
Algus
Hajus
Täpne
Lihtotsing Tühjenda
  • Leitud 32 kirjet
ProgrammLiikNumberNimiProjekti algusProjekti lõppVastutav täitjaAsutusFinantseerijapoolne rahastamine
ETFETF7408 Bakteriaalsed meningiidid Eestis: epidemioloogia ja kaugtulemused 01.01.200831.12.2011Pille TabaTartu Ülikool, Arstiteaduskond68 200,86 EUR
1.1.5.2.1.33.SARAI120119T (3.2.1001.11-0032)Antibiootikumide doseerimine raskete infektsioonide korral01.01.201231.08.2015Joel StarkopfTartu Ülikool; Tartu Ülikool, Arstiteaduskond434 558,70 EUR
RITA1AlamprojektLMVBS19497 (RITA1/02-75-02)Antibiootikumiresistentsuse levikuteed ja resistentsuse ohjamise võimalused01.07.201930.06.2022Irja LutsarTartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut158 015,00 EUR
MUUMARMB10129ARPEC - Antibiootikumide kasutamine ja resistentsus lastel Euroopas01.04.201031.03.2013Irja LutsarTartu Ülikool; Tartu Ülikool, Arstiteaduskond, Mikrobioloogia instituut16 068,03 EUR
MUUSARTH12115T (3.2.1001.11-0020)Bridging the gap in knowledge and practice of prevention and care for HIV in Estonia24.10.201131.08.2015Anneli UuskülaTartu Ülikool514 964,50 EUR
MUUMARMB06151RConcerted Action on SeroConversion to AIDS and Death in Europe01.03.200628.02.2010Irja LutsarTartu Ülikool45 450,00 EUR
1.2.3.4.MMVBS18106R (777389)conect4children- COllaborative Network for European Clinical Trials For Children01.05.201830.04.2024Irja LutsarTartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut1 174 750,00 EUR
1.2.3.4.MMVBS17039REesti Lasteuuringute Võrgustik01.01.201730.06.2021Irja LutsarTartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut48 750,00 EUR
1.1.7.1.SMVBS20555Eesti SARS-CoV-2 täisgenoomide järjestamine ja analüüs01.09.202031.12.2021Irja LutsarTartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut204 000,00 EUR
MUUVARMB13178EuroCoord - European Network of HIV/AIDS cohort studies to coordinate at European and International level clinical research on HIV/AIDS27.10.201031.12.2015Irja LutsarTartu Ülikool; Tartu Ülikool, Arstiteaduskond, Mikrobioloogia instituut36 000,00 EUR
SFSF0182726s06HIV infektsioon Eestis: viiruse ja peremeesorganismi interaktsioonid molekulaarsel ja kliinilisel tasandil01.01.200631.12.2011Irja LutsarTartu Ülikool, Arstiteaduskond372 766,67 EUR
SFSF0180004s12Infektsioon immuunsüsteemi häirega isikutel - haiguse mehhanimidest kliinilise praktikani01.01.201231.12.2014Irja LutsarTartu Ülikool, Arstiteaduskond349 080,00 EUR
IUTIUT34-24Infektsioonid langenud immuunsusega isikutel – eksperimendist kliinilisse praktikasse01.01.201531.12.2020Irja LutsarTartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut698 400,00 EUR
1.2.3.4.MMVBS18064RInfradev - European Paediatric Translational Research Infrastructure 01.01.201831.12.2019Irja LutsarTartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut34 375,00 EUR